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ABSTRACT 
Lung cancer remains the leading cause of cancer deaths worldwide, with the majority 
of cases attributed to non-small cell lung carcinomas. At the time of diagnosis, a large 
percentage of patients present with advanced stage of disease, ultimately resulting in 
a poor prognosis. The identification circulatory markers, overexpressed by the tumour 
tissue, could facilitate the discovery of an early, specific, non-invasive diagnostic tool 
as well as improving prognosis and treatment protocols. The aim was to analyse gene 
expression data from both microarray and RNA sequencing platforms, using 
bioinformatics and statistical analysis tools. Enrichment analysis sought to identify 
genes, which were differentially expressed (p < 0.05, FC > 2) and had the potential to 
be secreted into the extracellular circulation, by using Gene Ontology terms of the 
Cellular Component. Results identified 1 657 statically significant genes between 
normal and early lung cancer tissue, with only 1 gene differentially expressed (DE) 
between the early and late stage disease. Following statistical analysis, 171 DE genes 
selected as potential early stage biomarkers. The overall sensitivity of RNAseq, in 
comparison to arrays enabled the identification of 57 potential serum markers. These 
genes of interest were all downregulated in the tumour tissue, and while they did not 
facilitate the discovery of an ideal diagnostic marker based on the set criteria in this 
study, their roles in disease initiation and progression require further analysis. 
Key Words: lung cancer, early diagnosis, bioinformatics, gene enrichment analysis, 
microarray, RNAseq 
 
 
 
 
 
 
 v 
TABLE OF CONTENTS 
DECLARATION         ii 
ACKNOWLEDGEMENTS        iii 
ABSTRACT          iv 
TABLE OF CONTENTS        v 
LIST OF ABBREVIATIONS       xii 
LIST OF FIGURES                  xviii 
LIST OF TABLES                   xxii 
LIST OF APPENDICES                 xxiv 
Chapter 1: Literature Review 
1.1. Cancer Overview         1 
1.2. Carcinogenesis          2 
1.2.1. Sustaining Proliferative Signaling      4 
1.2.2. Evading Growth Suppressors       4 
1.2.3. Resisting Cell Death        5 
1.2.4. Enabling Replicative Immortality      6 
 
 
 
 
 
 
 vi 
1.2.5. Inducing Angiogenesis        7 
1.2.6. Activating Invasion and Metastasis      8 
1.3. Lung Cancer          8 
1.4. Classification of Lung Cancer       9 
1.5. Genetic Alterations in Lung Carcinomas     11 
1.6. Epigenetics and Lung Cancer       13 
1.7. Causes and Risk Factors Associated with Lung Cancer    15 
1.8. Staging and Grading        15 
1.9. Diagnosis of Lung Cancer       17 
1.10. Treatment and Prognosis       18 
1.11. The Burden of Disease of Lung Cancer     20 
1.12. Biomarker Application in Cancer      22 
1.13. Lung Cancer Biomarkers       23 
1.14. Protein Biomarkers        24 
1.15. Gene Biomarkers        25 
1.16. Sources of Biomarkers        27 
 
 
 
 
 
 
 vii 
1.17. Applications of Bioinformatics into Biomarker Discovery   29 
1.18. Biomarker Validation        31 
1.19. Aims and Objectives        33 
1.20. References          34 
Chapter 2: Identification of Potential Circulatory Biomarkers using Microarray 
Data 
2.1. Introduction          43 
2.2. Data Mining          43 
2.2.1. Microarray Data Mining       44 
2.2.2. Digital Expression Profiling using EST and SAGE    46 
2.3. Biological Databases        47 
2.3.1. Oncomine          47 
2.3.2. Gene Expression Atlas        48 
2.3.3. Intergrative OncoGenomics       48 
2.3.4. C-It          48 
2.3.5. Tissue-specific Gene Expression and Regulation    49 
 
 
 
 
 
 
 viii 
2.3.6. VeryGene          49 
2.3.7. Database for Annotation, Visualisation and Integrated Discovery  50 
2.4. Text Mining          50 
2.4.1. Text Mining Databases        51 
2.4.1.1. The Universal Protein Knowledgebase     51 
2.4.1.2. PolySearch          51 
2.4.1.3. Human Genome Epidemiology Network     52 
2.4.1.4. Google Scholar        52 
2.5. Materials and Methods        54 
2.5.1. Extraction of Candidate Gene Biomarkers     54 
2.5.1.1. Oncomine Database        55 
2.5.1.2. Gene Expression Atlas Database      56 
2.5.1.3. IntOGen Datatbase        56 
2.5.1.4. C-It Database         56 
2.5.1.5. TiGER Database        57 
2.5.1.6. VeryGene Database        57 
 
 
 
 
 
 
 ix 
2.5.1.7. Excluded Databases        57 
2.5.2. Analysis of Gene Lists        57 
2.5.2.1. Functional Characterisation using DAVID     57 
2.5.3. Literature Mining of Candidate Entities     58 
2.6. Results and Discussion        59 
2.6.1. Identification of Eligible Cancer Biomarkers     59 
2.6.2. Gene Enrichment Analysis       62 
2.6.3. Literature Mining of Candidate Genes      66 
2.7. Discussion and Conclusion       67 
2.8. References         72 
Chapter 3: Identification of Potential Circulatory Biomarkers using RNAseq 
Data 
3.1. Introduction         79 
3.2. Next Generation Sequencing       79 
3.2.1. RNA Sequencing        80 
3.2.1.1. RNAseq Version 2        82 
 
 
 
 
 
 
 x 
3.3. The Cancer Genome Atlas       83 
3.4. Bioinformatics Analysis Tools       84 
3.4.1. Bioinformatics Enrichment Tools      84 
3.4.1.1. MultiExperiment Viewer       86 
3.4.1.2. Enrichr         87 
3.4.2. Databases and Platforms       88 
3.4.2.1.1. Molecular Signatures Database      88 
3.4.2.2. Gene Expression Atlas       89 
3.5. Materials and Methods        90 
3.5.1. Data Retrieval from TCGA       90 
3.5.2. Analysis of Data using Bioinformatics Tools     91 
2.5.2.1. Analysis using MultiExperiment Viewer     91 
3.5.2.2. Enrichment Analysis using Enrichr      93 
3.5.2.2.1. Ontology Annotation Sources      93 
3.5.3. Gene Expression Analysis       94 
3.5.3.1. Molecular Signatures Database      94 
 
 
 
 
 
 
 xi 
3.5.3.2. Gene Expression Atlas       95 
3.6. Results and Discussion        95 
3.6.1. Data Collection from TCGA       95 
3.6.2. Statistical Analysis using MultiExperiment Viewer    96 
3.6.3. Enrichment Analysis using Enrichr Feature and Annotation Tool            100 
3.6.4. Expression Analysis                             112 
3.7. Discussion and Conclusion                 114 
3.8. References                    117 
Chapter 4: Future Perspectives                 129 
4.1. References                    132 
Appendices                     135 
 
 
  
 
 
 
 
 
 
 xii 
LIST OF ABBREVIATIONS 
IARC   : International Agency for Research on Cancer 
WHO   : World Health Organization 
RB   : Retinoblastoma 
P53   : Tumour protein P53 
G0   : Rest phase of cell cycle 
DNA   : Deoxyribonucleic acid 
ECM   : Extracellular matrix 
NSCLC  : Non-small cell lung carcinomas 
SCLC   : Small-cell lung cancer 
EGFR   : Epidermal growth factor receptor 
KRAS   : Kirsten rat sarcoma viral oncogene homolog 
p16   : Cyclin-dependent kinase inhibitor 2A 
RNA   : Ribonuclueic acid 
miRNA  : Micro ribonucleic acid 
CpG   : Cytosine phosphate guanosine 
mRNA   : Messenger RNA 
SNP   : Single-nucleotide polymorphism 
TNM   : Tumour node metastasis 
NCI   : National Cancer Institute 
AJCC   : American Joint Committee on Cancer 
IUCC   : International Union for Cancer Control 
 
 
 
 
 
 
 xiii 
CT   : Computerized tomography 
MRI   : Magnetic resonance imaging 
PET   : Positron emission tomography 
SEER   : Surveillance, Epidemiology, and End Results 
RNase   : Ribonuclease 
H. influenza  : Haemophilus influenza 
cDNA : Complementary DNA  
EST : Expressed Sequence Tags 
SAGE   : Serial Analysis Gene Expression 
MPPS   : Massively parallel signature sequencing 
HT   : High-throughput 
MS   : Mass spectrometry 
DE   : Differentially expressed 
RT-PCR  : Real-time polymerase chain reaction 
ELISA   : Enzyme-linked, immunosorbent assays 
GSEA   : Gene set enrichment analysis 
RNAseq  : RNA sequencing 
DEG   : Differentially expressed genes 
KDD   : Knowledge Discovery in Databases 
GO   : Gene Ontology 
GEA   : Gene Expression Atlas 
EBI   : European Bioinformatics Institute 
IntOGen  : Integrative OncoGenomics 
 
 
 
 
 
 
 xiv 
TiGER   : Tissue-specific Gene Expression and Regulation 
TSG   : tissue-specific gene 
CRM   : cis-regulatory module 
KEGG   : Kyoto Encyclopedia of Genes and Genomes  
MGI   : Mouse Genome Informatics 
DAVID  : Database for Annotation, Visualization and 
    Integrated Discovery 
UniProtKB  : The Universal Protein Knowledgebase 
HuGENet  : Human Genome Epidemiology Network 
MeSH   : Medical Subject Headings 
NCBI   : National Center for Bioinformatics 
CC   : Cellular components 
MF   : Molecular function 
BP   : Biological process 
CGAP   : Cancer Genome Characterization Initiative 
COPZ1  : Coatomer Protein Complex, Subunit Zeta 1 
SEC23B  : S. Cerevisiae Homolog B 
SEC24A  : (S. Cerevisiae Family Member A) 
SEC24D  : (S. Cerevisiae Family Member D) 
NGS   : Next Generation Sequencing 
CDS   : Coding DNA sequence 
RNAseq V2  : RNASeq Version 2 
 
 
 
 
 
 
 xv 
RPKM   : Reads Per Kilobase of exon model per Million 
TCGA   : The Cancer Genome Atlas 
RSEM   : RNAseq by Expectation-Maximization 
NHGRI  : National Human Genome Research Institute 
LUAD   : Lung adenocarcinoma 
LUSC   :  Lung squamous cell carcinoma 
SEA   : Singular enrichment analysis 
MEA   : Modular enrichment analysis 
MeV   : MultiExperiment Viewer 
KEA   : Kinase enrichment analysis 
GeneSigDB  : Gene Signatures Database 
MSigDB  : Molecular Signatures Database 
OMIM   : Online Mendelian Inheritance in Man 
N   : Normal lung tissue 
E   : Early stage lung cancer (Stage I & II) 
L   : Late stage lung cancer (Stage III & IV) 
TDMS   : Tab delimited, Multiple Sample Files 
FDC   : False discovery corrections 
FDR   : False discovery rate 
FC   : Fold change 
HCL   : Hierarchical clustering 
CS   : Combined score 
GPRC   : G-protein coupled receptors 
 
 
 
 
 
 
 xvi 
MGI   : Midrand Graduate Institute 
MP   : Mammalian Phenotype 
Ca
2+
   : Calcium 
GEO   : Gene Expression Omnibus 
PPI   : Protein-protein interactions 
ANGPTL7  : Angiopoietin-like 7 
EDN3   : Endothelin 3 
RETN   : Resistin 
NRG3   : Neuregulin 3 
CMTM2  : CKLF-like MARVEL transmembrane domain  
    containing 2 
CAMP   : Cathelicidin antimicrobial peptide  
FGF10   : Fibroblast growth factor 10 
AGRP   : Agouti related neuropeptide 
ANGPTL5  : Angiopoietin-like    
CMTM5  : CKLF-like MARVEL transmembrane domain 
    containing 5) 
FGF   : Fibroblast growth factor 
IRX1   : Iroquois homeobox 1 
ITLN2   : Intelectin 2 
CD5L   : CD5 molecule-like 
FIGF   : c-fos induced growth factor 
VEGFD  : Vascular endothelial growth factor D 
 
 
 
 
 
 
 xvii 
WNT   : Wingless type proteins 
WNT7A  : Wingless type protein family member  
JNK   : cJun N-terminal kinase 
GRIA1  : Glutamate receptor, ionotropic, AMPA 1 
CHRM1  : Cholinergic receptor, muscarinic 1 
CHRM2  : Cholinergic receptor, muscarinic 2 
HOP92  : Lung adenocarcinoma cell line 
HOP62  : Lung adenocarcinoma cell line 
A549   : Lung adenocarcinoma cell line 
NCI H23   : Lung adenocarcinoma cell line 
EKVX   : Lung adenocarcinoma cell line 
NCI 460  : Large cell lung carcinoma cell line 
NCI H322  : Unspecified lung carcinoma cell line 
NCI H226  : Squamous cell lung carcinoma cell line 
IM   : Immunofluorescence 
2D-PAGE  : Two- dimensional polyacrylamide gel 
    electrophoresis 
SELDI-ToF  : Surface enhanced laser desorption/ionisation time  
    of flight  
ICAT   : Isotope coded affinity tags 
MudPIT  : Multidimensional protein identification technology 
 
 
 
 
 
 
 
 
 xviii 
LIST OF FIGURES 
Figure 1.1: Cancer as the consequence of combined genetic and epigenetic 
alterations (Herceg & Hainaut 2007)………………………………………………….3 
Figure 1.2: The six biological hallmarks of cancer (Hanahan & Weinberg 
2011)…………………………………………………………………………………..3 
Figure 1.3: Molecular evolution of lung cancer. Showing the interaction of 
environmental factors, genetic susceptibility and unknown factors to influence 
carcinogenesis and resulting in genetic and epigenetic alterations, which influence the 
process of angiogenesis and metastases (Esteller 2008)……………………................9 
Figure 1.4: Genetic mutations specific to SCLCs and NSCLCs (Esteller 
2008)…………………………………………………………………………………13 
Figure 1.5: Lung cancer deaths and 5 year median survival rate in relation to (A) 
clinical stages and (B) pathologic stage (Detterbeck 2009)……………………........19 
Figure 1.6: Estimated new cancer diagnoses and deaths of most common types of 
cancer in the U.S. in 2014. With lung cancer displaying the 3rd most common cancer 
type, representing 13.5 % of all new cancer cases (National Cancer Institute (NCI), 
Surveillance, Epidemiology, and End Results (SEER) 
2015)…………………………………………………………………………………21 
 
 
 
 
 
 
 xix 
Figure 1.7: Mortality and incidence rates of lung cancer based on geographical 
location in females and males (Altintas & Tothill 2013)………………………........21 
Figure 1.8: Biocomputing tools for discovery and validation of biomarkers (Phan et 
al. 2009)……………………………………………………………………………...32 
Figure 2.1: Steps involved in knowledge discovery (Fayyed et al. 
1996)………………………………………………………………………………....44 
Figure 2.2: Outline of the methodology for biomarker discovery…………………..54 
Figure 2.3: Functional characterisation of genes in DAVID based on their biological 
process using GO analysis…………………………………………………………...63 
Figure 2.4: Functional characterisation of genes in DAVID based on their cellular 
component using GO analysis………………………………………………….........64 
Figure 2.5: Functional characterisation of genes in DAVID based on their molecular 
function using GO analysis…………………………………………..........................65 
Figure 3.1: The typical infrastructure of enrichment tools with three distinct layers: 
backend annotation database, data mining, and result presentation (Huang et al. 
2009)…………………………………………………………………………………85 
Figure 3.2: Expression matrix displaying rows of genes with high (red) and low 
(green) expression in relation to samples in each column generated by MeV v4.9 
(http://tm4.org/mev.html)………………………………………………………........87 
 
 
 
 
 
 
 xx 
Figure 3.3: Methodological approach for the retrieval and analysis of lung 
adenocarcinoma RNAseq V2 Level 3 data from the Cancer Genome 
Atlas…………………………………………………………………………….........90 
Figure 3.4: Gene expression data of LUAD between classes (N, E and L) generated 
from TCGA Level 3 RNAseq V2 data depicted using Venny 2.0.2 - Computational 
Genomics Service (bioinfogp.cnb.csic.es/tools/venny)……………………………...96 
Figure 3.5: DEG identified in classes E vs. N using MeV parametric t-Tests and 
multiple FDC (t-Test 1: p ≤ 0.01, no correction, t-Test 2: p ≤ 0.05 and Bonferroni, t-
Test 3: p ≤ 0.05 and maxT) depicted using Venny 2.0.2 – Computational Genomics 
Service (bioinfogp.cnb.csic.es/tools/venny)…………………………………………99 
Figure 3.6: Unique DEG between classes E vs. L identified using MeV parametric t-
Test 1, p ≤ 0.01, depicted using Venny 2.0.2 – Computational Genomics Service 
(bioinfogp.cnb.csic.es/tools/venny)………………………………………………....99 
Figure 3.7: DEG identified between classes N vs. L using parametric t-Tests and 
multiple FDC (t-Test 1: p ≤ 0.01, no correction, t-Test 2: p ≤ 0.05 and Bonferroni, t-
Test 3: p ≤ 0.05 and maxT) in MeV, depicted using Venny 2.0.2 Computational 
Genomics Service (bioinfogp.cnb.csic.es/tools/venny)…………………………….100 
Figure 3.8: Unique DEG in classes E vs. N and E vs. L determined to be statistically 
significant following statistical analysis using MeV. Depicted using Venny 2.0.2 – 
 
 
 
 
 
 
 xxi 
Computational Genomics Service 
(bioinfogp.cnb.csic.es/tools/venny)………………………………………………...100 
Figure 3.9: Histogram of enriched GO terms of BP generated from annotation 
analysis in Enrichr………………………………………………………………….102 
Figure 3.10: Histogram of enriched GO terms of CC generated from annotation 
analysis in Enrichr………………………………………………………………….103 
Figure 3.11: Histogram of enriched GO terms of MF generated from annotation 
analysis in Enrichr………………………………………………………………….104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxii 
LIST OF TABLES 
Table 1.1: Summary of lung tumour types (Herceg & Hainaut 2007; Herbst et al. 
2008; Patel et al. 2008)………………………………………………………………11 
Table 1.2: Cancer staging based on TNM criteria (Detterbeck 
2009)……………………………………………………………………………16 
Table 1.3: Lung cancer protein biomarkers currently available (Sung & Cho 2008; 
Altintas & Tothill 
2013)……………………………………….………………………..................25 
Table 1.4: Genes and associated mutation types reported in lung cancer (Sung & 
Cho 2008; Altintas & Tothill 
2013)……………………………………………..….………………................27 
Table 2.1: Summary of genes extracted from 
Oncomine………………………………………………………………………...60 
Table 2.2: Summary of genes extracted from GEA based on GO 
terms……………60 
Table 2.3: Summary of genes extracted from 
databases……………………………………………………………...……….....61 
Table 3.1: Statistical parameters implemented to identify DEG between LUAD N, 
E and L samples using 
MeV………………………………………….…………………………………...92 
Table 3.2: Ontology enrichment terms extracted from Enrichr (p < 0.01, (CS) > 
2)……………………………………………………………………………………105 
 
 
 
 
 
 
 xxiii 
Table 3.3: Pathway enrichment terms extracted from Enrichr (p < 0.01, (CS) > 
2)……………………………………………………………………………………108 
Table 3.4: Candidate genes identified as located in the extracellular cellular 
component using GO annotations and having the potential to be serum 
markers……………………………………………………………………………..110 
Table 3.5: Genes of interest identified using annotation, statistical analysis and 
enrichment analysis………………………………………………………………...111 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 xxiv 
LIST OF APPENDICES 
Appendix A: Average sample means of groups early versus normal lung cancer 
used to identify genes as downregulated (FC > 
2)…………………………………………………………………….………….137 
Appendix B: Heat map visulisation of oncogenic signatures of candidate genes of 
interest generated by the Molecular Signatures Database (MSigDB) NCI-60 cell line 
(National Cancer Institute) with red indicating upregulation and blue depicting 
downregulation (http://www.broadinstitute.org/msigdb)…………………………..142 
Appendix C: Heat map visulisation of oncogenic signatures of candidate serum 
markers generated by the Molecular Signatures Database (MSigDB) NCI-60 cell line 
(National Cancer Institute) with red indicating upregulation and blue depicting 
downregulation (http://www.broadinstitute.org/msigdb)…………………………..143 
 
 
 
 
 
 
 
1 
 
Chapter 1 
Literature Review 
1.1. Cancer Overview 
Cancer arises as the result of abnormal cell growth and can be identified as a hyper-
proliferative disorder, characterized by deregulation of apoptosis, increased cell 
proliferation, cell invasion, angiogenesis as well as metastasis (Cooper & Hausman 
2007; Herceg & Hainaut 2007). A tumour, an abnormal mass of cells is defined as 
either malignant or benign. A benign tumour does not invade surrounding tissue or 
spread to distant body sites and remains confined to its location of origin. A 
malignant tumour is capable of both invasion of surrounding tissue as well as 
metastasis via the lymphatic or circulatory systems (Cooper & Hausman 2007). 
Tumours are classed according to the type of cell from which they arise, and 
commonly fall into three main groups: carcinomas, sarcomas and leukemias or 
lymphomas (Cooper & Hausman 2007; Herceg & Hainaut 2007). Approximately 90 
% of all malignancies are carcinomas, which are malignancies of epithelial tissue. 
Less common in humans is sarcomas, which are solid tumours of connective tissues 
such as; bone, muscle, cartilage and fibrous tissue. Leukemias and lymphomas 
originate from blood forming cells and cells of the immune system, respectively and 
account for approximately 8 % of human cancers (Cooper & Hausman 2007). 
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According to the International Agency for Research on Cancer (IARC) and World 
Health Organization (WHO), cancer is a leading cause of death worldwide, resulting 
in 8.2 million deaths in 2012. The IARC estimates that annual cancer cases will rise 
from 14 million in 2012 to 22 million in the next two decades (De Martel et al. 2012; 
Stewart & Wild 2014). 
The most common human cancers, accounting for more than half of all neoplasias 
are; breast, prostate, lung and colon cancers, with lung cancer being by far the most 
lethal and resulting in approximately 30 % of all cancer deaths (Cooper & Hausman 
2007; Stewart & Wild 2014). 
1.2. Carcinogenesis 
Carcinogenesis occurs due to the accumulation of genetic as well as epigenetic 
alterations, which alter the structure and/or function of the genome (Figure 1.1). 
These changes can be induced by dietary and/or environmental factors which trigger 
inappropriate activation or inactivation of specific genes which result in neoplastic 
transformation (Herceg & Hainaut 2007). Studies conducted by Hanahan and 
colleagues (2000) demonstrated that the transformation of a primary cell into a 
malignant one, involves alterations in mechanisms governing cell growth, 
homeostatic balance, cell differentiation and cell death (Figure 1.2) (Herceg & 
Hainaut 2007). More specifically there are six biological hallmarks of cancer. 
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Figure 1.1: Cancer as the consequence of combined genetic and epigenetic 
alterations (Herceg & Hainaut 2007). 
Figure 1.2: The six biological hallmarks of cancer (Hanahan & Weinberg 2011). 
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1.2.1. Sustaining Proliferative Signaling 
One of the most important characteristics of tumour cells is their ability to sustain cell 
proliferation. The uncontrolled growth of malignancies distinguishes them from their 
normal counterparts (Cooper & Hausman 2007; Stratton et al. 2009). In normal cells, 
production and release of growth-promoting signals control homeostasis through cell 
growth and division cycles. These signals are communicated by growth factors, 
which bind cell-surface receptors, commonly containing tyrosine kinase domains. 
The receptors proceed to emit signals through branched intracellular pathways to 
regulate cell cycle progression (Hanahan & Weinberg 2011). 
Cancer cells however, are able to deregulate these mechanisms resulting in 
uncontrolled proliferation. The ability of a tumour to sustain proliferation may be 
brought about in several ways. In some cases, cancer cells may produce growth factor 
ligands themselves, resulting in autocrine proliferation stimulation. Alternatively 
tumour cells may signal normal cells within the neoplasia to supply the cancer cells 
with growth signals. In other instances the reduced growth factor dependence of the 
tumour may result from elevated levels of receptors at the cancer cell surface (Cooper 
& Hausman 2007; Hanahan & Weinberg 2011; Chaffer & Weinberg 2011). 
1.2.2. Evading Growth Suppressors  
Within normal tissues, various anti-proliferative signals maintain cellular quiescence 
and homeostasis. These signals include soluble growth inhibitors and inhibitors 
embedded in the extracellular matrix and on surfaces of nearby cells (Hanahan & 
 
 
 
 
 
 
5 
 
Weinberg 2011; Stratton et al. 2009). The ability to bypass anti-proliferative signals 
is another fundamental trait of cancer cells. These signals are most typically regulated 
by tumour suppressor genes. Numerous tumour suppressors act in various ways to 
limit cell growth as well as proliferation. The two quintessential tumour suppressor 
genes encode the retinoblastoma (RB) and tumour protein P53 (P53) proteins which 
operate as central controls within two complementary cell regulatory circuits of cell 
proliferation (Chaffer & Weinberg 2011; Hanahan & Weinberg 2011). The RB 
protein integrates signals from both extracellular as well as intracellular sources and 
determines whether a cell would proceed through its growth and division cycle. 
While RB responds largely to extracellular signaling; P53 receives input from stress 
intracellularly, acting to halt proliferation or cause the cell to undergo apoptosis. 
Tumour cells with defects in the RB or P53 pathway are therefore, lacking important 
gatekeepers of cell cycle proliferation which may cause cells to cease proliferation 
and enter the G0 (rest) phase of the cell cycle (Hanahan & Weinberg 2000; Hanahan 
& Weinberg 2011). 
1.2.3. Resisting Cell Death 
Apoptosis, programmed cell death, is a mechanism that enables multi-cellular 
organisms to tightly regulate or control cell growth in order to prevent pathological 
processes such as cancer (Simon et al. 2000). Apoptosis is triggered in response to 
various physiological stresses such as deoxyribonucleic acid (DNA) damage 
associated with hyper-proliferation and signaling imbalances, due to elevated levels 
of oncogenes (Brodie & Blumberg 2003; Hanahan & Weinberg 2011). Oncogenes are 
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mutated genes, which initially acted in cell cycle regulation. The failure of cancer 
cells to undergo apoptosis ultimately contributes substantially to tumour development 
(Cooper & Hausman 2007; Simon et al. 2000). Tumor cells utilize a variety of 
strategies to resist apoptosis, the most common being the loss of P53 tumor 
suppressor function. Tumors may also evade apoptosis by elevating expression of 
anti-apoptotic regulators or by down-regulating pro-apoptotic factors of survival 
signals (Hanahan & Weinberg 2011; Gibbons et al. 2014). 
 1.2.4. Enabling Replicative Immortality 
Cancer cells require an infinite replicative potential in order to produce macroscopic 
tumours. This is in direct contrast to the tumours’ normal cell counterparts, which 
only pass through a limited number of successive cell growth and division cycles. 
This limitation has been associated with two barriers to proliferation, namely; 
senescence, the irreversible entrance into a non-proliferative but viable state, and 
crisis, which results in cell death. Rarely do the cells emerge from crisis, this 
transition is called immortalization (Hanahan & Weinberg 2011). 
Telomeres, which protect the ends of chromosomes, are implicated in being 
intricately involved in unlimited proliferation. In non-immortalized cells, telomeres 
shorten progressively, eventually losing the ability to protect the chromosomal DNA 
(Hanahan & Weinberg 2000; Hanahan & Weinberg 2011). The length of telomeric 
DNA also dictates the number of successive cell generations it may pass through 
before entering into crisis. Telomerase, a specialized DNA polymerase, adds telomere 
 
 
 
 
 
 
7 
 
repeat segments to the ends of telomeric DNA and is generally absent in normal cells 
but may be highly expressed in immortalized cells such as human cancer cells 
(Hanahan & Weinberg 2000; Chaffer & Weinberg 2011). By extending the telomeric 
DNA, telomerase counters the normal erosion that should occur. The presence of 
telomerase activity is directly correlated with resistance of both senescence and 
apoptosis (Simon et al. 2000; Hanahan & Weinberg 2011). 
1.2.5. Inducing Angiogenesis  
Tumours secrete growth factors that promote the formation of new blood vessels 
(angiogenesis). Angiogenesis is necessary to support growth beyond the size of an 
estimated million cells, which at this point require new blood vessels to supply 
oxygen and nutrients to the proliferating cancer cells. Blood vessels are formed in 
response to growth factors, secreted by the tumor cells that stimulate proliferation of 
endothelial cells within the walls of capillaries in surrounding tissue. This results in 
the outgrowth of new capillaries into the tumor (Sabine et al. 2002). The formation of 
such new blood vessels is critical not only in supporting tumor growth, but also in 
metastasis. The actively growing new capillaries formed in response to angiogenic 
stimulation are easily penetrated by the tumor cells, providing a ready opportunity for 
cancer cells to enter the circulatory system and begin the metastatic process (Cooper 
& Hausman 2007; Garraway & Lander 2013). 
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 1.2.6. Activating Invasion and Metastasis 
Most cancer cells are less adhesive than normal cells, often as a result of reduced 
expression of cell surface adhesion molecules. The reduced adhesiveness also results 
in morphological and cytoskeletal alterations in which many tumor cells are 
resultantly rounder than normal, in part because of the reduced attachment to either 
the extracellular matrix (ECM) or neighboring cells (Cooper 2000; Hunter et al. 2008; 
Hanahan & Weinberg 2011). Tumor cells are able to migrate and continue moving 
after contact with their neighbors, migrating over adjacent cells, and growing in 
disordered, multilayered patterns. The multistep process of invasion and metastasis is 
a distinct sequence of events often termed the invasion-metastasis cascade. This 
begins with local invasion, followed by intravasion of the cancer cells into the blood 
and lymphatic vessels and then the escape of the cancer cells into distant tissues and 
the formation of cancer nodules or micrometastasis resulting in the formation of 
tumours (Kenific et al. 2010; Hanahan & Weinberg 2011). 
1.3. Lung Cancer 
The molecular origins of lung cancer are the consequence of complex interactions 
between the environment and combined genetic and epigenetic host susceptibility 
(Figure 1.3) (Herceg & Hainaut 2007; Herbst et al. 2008). Certain environmental 
factors and genetic susceptibility may influence the initiation or promotion of 
carcinogenesis. The former may result in tissue injury, which initially can be seen in 
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the form of genetic and epigenetic alterations (Panov 2005; Herceg & Hainaut 2007; 
Herbst et al. 2008) 
 
 
Figure 1.3: Molecular evolution of lung cancer. Showing the interaction of 
environmental factors, genetic susceptibility and unknown factors to influence 
carcinogenesis and resulting in genetic and epigenetic alterations, which influence 
the process of angiogenesis and metastases (Esteller 2008). 
1.4. Classification of Lung Cancer 
Lung cancer can be classified based on the size and appearance of the malignant cells 
(Table 1.1) as either; non-small cell lung carcinomas (NSCLC) or small-cell lung 
cancer (SCLC) (Travis et al. 2004). NSCLC can be further histologically categorized 
as; squamous cell carcinoma, adenocarcinoma and large cell lung carcinoma. 85 % of 
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all lung cancers are attributed to NSCLC, of which squamous cell carcinoma is most 
common in males and adenocarcinoma in females and non-smokers (Wynder & 
Muscat 1995; Johnson 1998; Brescia 2001). 
Lung tumours present with heterogeneous patterns of genetic and epigenetic changes 
as well as gene expression, even in homogenous histological groups (Herceg & 
Hainaut 2007). Each class of tumour can be seen to progress via a different 
mechanism of carcinogenesis in association with specific genetic lesions (Wakamatsu 
et al. 2007). Lung carcinomas related to smoking display a very different molecular 
profile when compared to lung cancers unrelated to tobacco products (Herceg & 
Hainaut 2007). Studies report that epidermal growth factor receptor (EGFR) kinase 
mutations are observed in early adenocarcinoma development in never smokers, 
whilst mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are seen in 
smokers (Herceg & Hainaut 2007; Herbst et al. 2008). Squamous cell carcinoma and 
SCLC are most commonly related to tobacco smoke and generally develop in the 
central airway. Tumours usually unrelated to smoking such as adenocarcinomas, tend 
to develop in the peripheral airways (Esteller 2008). 
 
 
 
 
 
Table 1.5: Summary of lung tumour types (Herceg & Hainaut 2007; Herbst et al. 
2008; Patel et al. 2008) 
 Non-small Cell Carcinomas 
 
Small Cell 
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Squamous Cell 
Carcinomas 
Adenocarcinomas 
Large Cell 
Carcinomas 
Carcinomas 
Incidence (%) 55 15 5 25 
Gender 
Incidence 
M>F F>M M>F M>F 
Location Hilar Peripheral Peripheral/Central Hilar 
Histological 
Stain 
keratin mucin - - 
Relationship to 
Smoking 
High Low High High 
Growth Rate Slow Medium Rapid Very rapid 
Metastasis Late Intermediate Early Very early 
Prognosis 2 year survival rate = 50 % 1 year if treated 
 
1.5. Genetic Alterations in Lung Carcinomas 
Overall, genetic alterations disrupt normal patterns of gene expression, which can 
result in abnormal expression of proteins (Herceg & Hainaut 2007; Liloglou et al. 
2014). DNA damage in the lung may fail to be repaired, resulting in incorrect 
nucleotide incorporations and ultimately mutations (Massion & Carbone 2003). 
Studies have revealed that in a single tumour, approximately 11 genes, including 
oncogenes and tumour suppressor genes, were mutated at a significant level (Herceg 
& Hainaut 2007; Risch & Plass 2008). Mutations envelop a variety of structural 
changes in DNA and include; changes in chromosome copy numbers, chromosomal 
 
 
 
 
 
 
12 
 
alterations such as translocations, amplifications, deletions and changes in nucleotide 
sequences (Massion & Carbone 2003; Herceg & Hainaut 2007; El-Zein et al. 2012). 
EGFR is an example of a protein often over expressed as a result of a mutation and in 
the protein kinase domain. EGFR regulates important carcinogenic processes such as 
proliferation, apoptosis, angiogenesis and metastasis (Esteller 2008). Other often 
mutated functional domains involve DNA binding and transcriptional regulation 
domains (Herceg & Hainaut 2007).  
Alteration in the P53 tumour suppressor gene is a typical example of a DNA binding 
and transcriptional regulation domain mutation, and is present in two thirds of lung 
cancers (Massion & Carbone 2003). Other common genetic mutations include that of 
KRAS, an oncogene mutated in approximately 30 % of lung carcinomas and cyclin-
dependent kinase inhibitor 2A (p16), a tumour suppressor gene mutated in 
approximately 40 % of NSCLCs (Figure 1.4) (Wakamatsu et al. 2007; Estela et al. 
2010; Fang et al. 2013). Chromosomal translocation is the most common type of 
mutation, while the protein kinase domain is functionally most frequently encoded by 
cancer genes (Herceg & Hainaut 2007; Kandoth et al. 2013). 
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Figure 1.4: Genetic mutations specific to SCLCs and NSCLCs (Esteller 2008). 
 
1.6. Epigenetics and Lung Cancer 
Epigenetics refers to all hereditable alterations in genetic expression and chromatin 
structure which is not directly coded in the DNA sequence (Herceg & Hainaut 2007). 
Epigenetic mechanisms which include; DNA methylation, histone modifications, 
micro ribonucleic acid (microRNAs) (miRNAs) and nucleosome remodeling, work 
together to regulate gene expression (Risch & Plass 2008; Liloglou et al. 2014). 
Epigenetic changes deregulate important mechanisms such as transcriptional control 
leading to inappropriate gene activation or silencing (Kanwal & Gupta 2012; 
Liloglou et al. 2014). 
 
 
 
 
 
 
14 
 
DNA methylation is an early event in the process of lung cancer (Risch & Plass 
2008). Two types of DNA methylation are found in lung tumorigenesis; global 
hypomethylation, (the overall loss of 5-methyl-cytosine) contributing to genomic 
instability and gene promoter-associated hypomethylation (cytosine phosphate 
guanosine (CpG) island specific) (Herceg & Hainaut 2007; Liloglou et al. 2014). 
DNA promoter sequence methylation in association with histone tail modifications 
acts as the silencing mechanism of tumour suppressor genes. P16 is a tumour 
suppressor gene well studied in promoter-associated hypomethylation (Risch & Plass 
2008). 
MiRNAs, short, (20-22 nucleotides) non-coding RNAs capable of acting as either 
oncogenes or tumour suppressor genes, regulate gene expression post-
transcriptionally (Herceg & Hainaut 2007). They may therefore affect messenger 
RNA (mRNA) stability and translational rate (Laird 2003). To date two miRNAs, 
miR-23 and miR-225 have been found to be specific to NSCLCs (Liloglou et al. 
2014). 
In addition, recent genome association research found a correlation between single-
nucleotide polymorphism (SNP) variation at 15q 24-15q25.1 and lung cancer 
susceptibility. This SNP region includes two nicotinic acetylcholine alpha receptor 
genes encoding subunits which are regulated by nicotine exposure (Esteller 2008). 
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1.7. Causes and Risk Factors Associated with Lung Cancer 
Tobacco smoke is attributed to approximately 75 % of all lung cancer cases 
worldwide, with remaining cases being linked to other environmental factors, 
heritable conditions and chronic inflammatory diseases (Johnson 1998; Coté et al. 
2012). Despite the major correlation between cigarette smoke and lung cancer, lung 
carcinomas in never smokers represents the seventh leading cause of cancer related 
deaths globally (Pallis & Syrigos 2013). 
Epidemiological studies have shown an association between an increased risk of lung 
cancer development and family history (Esteller 2008). Risk of susceptibility to this 
form of cancer is also increased in patients with inherited cancer syndromes resulting 
from rare germ-line mutations in P53, RB and EGFR (Gibbons et al. 2014). 
1.8. Staging and Grading 
At the time of diagnosis, the progression of the cancer is an important factor used to 
determine a treatment protocol as well as prognosis. The TNM system is the most 
commonly used cancer staging system (Edge & Compton 2010; McLoud & Swenson 
1999). This system is accepted and maintained by the NCI (National Cancer 
Institute), American Joint Committee on Cancer (AJCC) and the International Union 
for Cancer Control (IUCC). It codifies cancers (Table 1.2) based on the size and 
extent of the primary tumour (T), the degree of spread to regional lymph nodes (N), 
and the presence of metastasis (M) or the formation of secondary tumours. A 
numerical index is added to each letter to indicate the extent of the primary tumour 
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and degree of cancer. These TNM combinations correspond to specific stages of 
cancer (Edge & Compton 2010; Edge et al. 2010). 
Using the TNM system, early stage lung carcinomas are classified to be that of Stage 
I and II while late stage lung carcinomas are deemed Stage III and IV. Stage I form of 
cancer is located solely in the lungs with no spread to any lymph nodes; Stage II 
represents a tumour in the lungs with nearby lymph node spread. Stage III is termed a 
locally advanced disease with cancer spreading to lymph nodes in the middle of the 
chest, which are considered to be outside the lung. The most advanced stage of lung 
cancer, Stage IV is when the disease has spread to both lungs, the fluid surrounding 
the lungs or any other organ of the body (Edge & Compton 2010; Maldonado & Jett 
2014).  
Table 1.6: Cancer staging based on TNM criteria (Detterbeck 2009).  
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1.9. Diagnosis of Lung Cancer 
Current diagnostic tools include; chest X-ray, computerized tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), sputum 
cytology and biopsy (Altintas & Tothill 2013). Chest radiography requires good view 
of both the posteroanterior and lateral lung regions. Chest X-rays demonstrate over 90 
% of carcinomas. However, the mass is required to be between 1-2 cm in size for a 
reliable diagnosis. Pleural effusions as well as lobar collapse may be present (Patel et 
al. 2008). CT scans allow for a more accurate visualization of the mediastinum and is, 
therefore, better at identifying smaller lesions. This form of diagnosis is used to 
assess the extent of the tumour metastases as well as the operability of the mass (Patel 
et al. 2008). 
In transthoracic fine-needle aspiration biopsy, a needle is guided by means of X-ray 
or CT. Direct aspiration of peripheral lung lesions occurs through the chest wall. 
Although implantation metastases does not occur, 25 % of patients may suffer a 
pneumothorax during this procedure (Patel et al. 2008; Altintas & Tothill 2013). 
These tools are expensive, tedious and may not be suitable for all cases, as other 
pathologies consider the needs of the patient. Individually it may also result in pain or 
complications for the patient (Altintas & Tothill 2013). At the time of diagnosis only 
20 % of all lung cancer cases are localized, with the remainder being distant 
metastatic carcinomas which are non-resectable (Patz et al. 2007; Tu 2010). Current 
diagnostic techniques do not allow for early stage diagnosis, or detection of lung 
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cancer in asymptotic patients, ultimately resulting in disease progression and a poor 
prognosis (Tu 2010). 
1.10. Treatment and Prognosis 
Surgery is currently the gold standard of NSCLC treatment, however, only 15 % of 
cases are operable at the time of diagnosis. Surgery is performed only upon 
confirmation of lung function tests displaying sufficient respiratory reserve, with no 
evidence of metastases on CT scans (Patel et al. 2008). Radiation treatment is often 
used for inoperable tumours and is effective particularly with slow growing 
squamous carcinomas. Radiation pneumonitis is a complication found in 
approximately 10-15 % of patients, while radiation fibrosis may occur in varying 
degrees in all cases (Patel et al. 2008; Flynn et al. 2013). Chemotherapy is the only 
effective treatment for SCLC, and is undertaken as a treatment therapy only and not a 
cure (Patel et al. 2008; Planque et al. 2009). Endoscopic therapy and transbronchial 
stenting may be used to provide symptomatic relief in patients. Daily administration 
of predinisone is used to improve appetite, while opiod analgesics are used to control 
pain (Brescia 2001; Patel et al. 2008). 
Within one year of diagnosis, 45 % of lung cancer patients die despite receiving 
treatment (Brescia 2001). The average 5 year survival rate (Figure 1.5) is only 10-
15 %, even patients presenting with clinical stage I lung cancer have a 60 % median 
survival rate of 5 years, indicating that a large portion of these patients possibly have 
undetectable metastatic lung cancer at the time of presentation of the disease (Patz et 
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al. 2007; Rose-James & TT 2012). The majority of NSCLC patients present with 
stage III and IV of the disease, those with stage IV cancer dying within 6-10 months 
of diagnosis (Brescia 2001). 
In patients who survive surgical resection of a NSCLC, the risk of developing a 
second lung carcinoma is approximately 1 % to 2 % and 6 % for SCLC. The median 
survival rate of a secondary lung cancer diagnosis in these patients is 1-2 years, with 
less than 20 % of these cancers being resectable (Nicholson et al. 2001; Zeng et al. 
2015). 
 
 
 
Figure 1.5: Lung cancer deaths and 5 year median survival rate in relation to (A) 
clinical stages and (B) pathologic stage (Detterbeck 2009). 
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1.11. The Burden of Disease of Lung Cancer 
Lung cancer remains a significant public health issue, resulting in the most cancer-
related deaths globally (Kim et al. 2007; Altintas & Tothill 2013). In 2012 lung 
cancer was responsible for 1.59 million deaths (De Martel et al. 2012). Variations in 
incidence rates of lung cancer can be seen based on age, gender and global 
geographical location, with the greatest incidence of disease being observed in men in 
eastern and central Europe and northern America (Altintas & Tothill 2013). 
Surveillance, Epidemiology, and End Results (SEER) statistics indicate that in the 
USA lung cancer represented 13.5 % of all new cancer cases (Figure 1.6) with an 
estimated 159 260 deaths predicted in 2014 (Howlader et al. 2015). This neoplasia 
presents with similar mortality and incidence rates in contrast to other common 
cancers such as breast, colon and prostate carcinomas with relatively low mortality 
rates. With approximately 22 % of all cancers stemming from this disease, it is the 
second most common cancer in men and third in women (Figure 1.7) (Altintas & 
Tothill 2013).  
With one in six males and one in eight females at risk of developing cancer, South 
Africa has one of the highest incidence rates of cancer in Africa (Albrecht 2006; 
Nema & Khare 2011). Data obtained from the National Cancer Registry (2004) 
showed lung cancer to be one of the leading cancers to affect South African males. In 
South Africa, lung cancer is the second most common cancer in men and the sixth 
leading cancer in women in terms of diagnosis (CANSA 2008). Approximately 60 % 
of all lung cancer deaths in South Africa are due to tobacco smoking with over 8 % of 
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all deaths attributed to smoking. Over 42 000 South Africans a year die of tobacco-
related diseases, which includes lung cancer (Mayosi et al. 2009).  
 
 
 
 
 
 
 
Figure 1.7: Mortality and incidence rates of lung cancer based on geographical 
location in females and males (Altintas & Tothill 2013). 
Figure 1.6: Estimated new cancer diagnoses and deaths of most common types of 
cancer in the U.S. in 2014. With lung cancer displaying the 3rd most common cancer 
type, representing 13.5 % of all new cancer cases (National Cancer Institute (NCI), 
Surveillance, Epidemiology, and End Results (SEER) 2015). 
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1.12. Biomarker Application in Cancer 
The main reason associated with poor prognosis is due to the difficulty in making an 
early stage diagnosis, unresectability as well as the high rate of recurrence after 
treatment (Brescia 2001; Kim et al. 2007). Currently no diagnostic tools exist that are 
able to detect lung cancer in asymptomatic patients. Indeed, a rapid, sensitive, easily 
applicable, non-invasive screening mechanism is needed to detect lung cancer at a 
stage in which intervention could alter the natural progression of the disease (Altintas 
& Tothill 2013; Vannini et al. 2013). 
Sophisticated molecular techniques have made it possible to detect genetic alterations 
in tumours; with research highlighting the fact that certain of these changes are 
specific to homogenous malignant diseases (Fleischhacker et al. 1999; Kim et al. 
2007). 
Tumour biomarkers are molecules used as indicators of biological homeostasis and 
are produced by cancer cells as a direct response by the body to the tumour (Altintas 
& Tothill 2013). Cancer markers can be differentiated into several distinct groups 
based on; genetics, epigenetics and proteomics (Sung & Cho 2008). 
Post-translational and translational expression analysis in single cells have to date 
identified many biomarkers as screening tools for cancer research. These research 
areas include; cancer diagnosis, prognosis and therapy development techniques, to 
predict the response to specific therapy types such as chemotherapy or evaluate the 
risk of future relapse (Schwarzenbach et al. 2011; Altintas & Tothill 2013). 
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Correct diagnosis of cancer using biomarkers is expected to significantly benefit in 
molecular based cancer patient care, with the potential to predict possible cancer 
progression and possibly prevent cancer development in individuals identified as high 
risk (Hassanein et al. 2012). These biomarkers are expected to not just predict 
predisposition but to also diagnose patients at an early stage of the disease. This 
would greatly increase the patients’ prognosis and ultimately decrease mortality. In 
addition, certain tumour markers, referred to as secondary biomarkers, change in 
expression levels in response to therapy and treatment and could be used as a guide to 
the most effective therapy required (Sung & Cho 2008). 
Thus molecular markers may potentially be used to signify risk in individuals without 
the disease, and in prognosis of those affected. It could also determine sensitivity to 
treatment, spanning the course of a disease through its various stages (Esteller 2008). 
It is unlikely that one single biomarker will meet all these conditions, due to the 
heterogeneity reported among cancers. It is also unrealistic that a single biomarker 
will provide the specificity and sensitivity necessary throughout the various stages of 
tumour progression and development (Phan et al. 2009). Therefore, identifying a 
panel of tumour markers would improve the efficacy of diagnosis as well as 
prognosis (Planque et al. 2009; Travis et al. 2011). 
1.13. Lung Cancer Biomarkers 
Unlike the specific parameters used in the TNM system, tumour markers are reported 
to be far more suited to the heterogenous nature of cancer (Sung & Cho 2008). 
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Biomarkers have greater potential for differential diagnosis and histological sub-
typing, particularly in lung carcinomas of unknown origins (Chi-Shing Cho 2007). 
Although lung cancer is histologically categorized into SCLC and NSCLC, there may 
be various other criteria dividing the sub-types such as genetic mutations. These 
specific sub-categories cannot be determined without the use of invasive biopsies and 
screening of tumour specific biomarkers, and may prove more useful in an attempt to 
accurately diagnose the cancer (Sung & Cho 2008). 
1.14. Protein Biomarkers 
The human genome is currently known to contain 20 488 genes. Proteins result in far 
greater variety due to post-translation modifications, protease cleavages and splice 
variants. This increase in variation implies that protein biomarkers can contribute 
more specificity to cancer type and status (Sung & Cho 2008; Makridakis & Vlahou 
2010).  
Protein lung cancer biomarkers can be classified from the source of the proteins into 
three categories, namely: serum biomarkers, tissue biomarkers, and sputum 
biomarkers with a broad range associated with lung cancer (Table1.3). The 
concentration and levels of these biomarkers however are quite complex. Both the 
specificity as well as the response ratio of the protein biomarkers show alterations 
depending on the histological subtype of the lung carcinoma (Altintas & Tothill 
2013). 
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Table 1.7: Lung cancer protein biomarkers currently available (Sung & Cho 2008; 
Altintas & Tothill 2013). 
 
1.15. Gene Biomarkers 
A large variety of genes have been exposed to somatic mutations in human tumour 
cells or tissue. These mutated genes include oncogenes and tumour suppressor genes 
as well as genes which encode proteins that perform vital functions in cell cycle 
regulation, DNA repair, apoptosis and telomerase activity (Altintas & Tothill 2013). 
 Diagnosis 
Therapy 
monitoring 
Prognosis 
monitoring 
Ontology 
Carcinoembryonic 
antigen 
(CEA) 
 
 
Adenocarcinoma 
Large cell lung 
cancer 
 
Adenocarcinoma 
NSCLC 
 
Adenocarcinoma 
NSCLC 
 
Cellular 
component 
Cytokeratin 
fragment 
(CYFRA 21-1) 
 
NSCLC, SCLC 
 
NSCLC 
 
NSCLC, SCLC 
 
Structural 
constituent of 
cytoskeleton 
Tissue polypeptide 
antigen 
(TPA) 
 
NSCLC, SCLC 
 
- 
 
NSCLC 
 
Progastrin-
releasing peptide 
(ProGRP) 
 
SCLC 
 
SCLC 
 
- 
 
Neuropeptide 
hormone activity 
 
Neuron-specific 
endolase 
(NSE) 
 
SCLC 
 
SCLC 
 
SCLC 
 
Phosphoglycerate 
dehydrogenase 
activity, sub-
cellular location 
 
Tumour M2 
pyruvate kinase 
 
Adenocarcinoma 
 
- 
 
Adenocarcinoma 
Pyruvate kinase 
activity, 
Glycolysis, 
Cytoplasm 
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A range of mutation types have also been identified, these include; missence, 
nonsense and splicing mutations, gene amplification, micro deletions, translocations 
and promoter hyper-methylation (Table 1.4). The roles of these somatic mutations 
play in lung carcinogenesis is understood in terms of their ability to promote cellular 
growth, interfere with DNA repair, evasion of host immunity, to confer resistance to 
apoptosis or to induce cellular transformation to name a few (Altintas & Tothill 2013; 
Fang et al. 2013). 
Inactivation of tumour suppressor genes during cell division is a key factor driving 
clonal cancer cells into hyper-proliferation, migration and metastasis. In many cases 
the inactivation is initiated by loss of DNA chromosomal rearrangement occurring 
during cell division. The most frequently occurring abnormality is deletion of the 
short arm of chromosome 3 (3p) (Altintas & Tothill 2013; Fang et al. 2013). Loss of 
chromosomal material has been reported to be detected in metaplastic epithelium 
tissue of smokers (Sung & Cho 2008). 
Altered hyper-methylation and methylation of CpG rich regions of several promoter 
regions is representative of epigenetic changes in the cell and may lead to gene 
silencing. Due to this, specific methylation status in genes can serve as biomarkers 
especially in tumour suppressor genes (Sung & Cho 2008). Activation of genes 
involves growth factors, their receptors, their messengers or cell cycle activators of 
mutations, which drives tumorigenesis (Estela et al. 2010). 
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Table 1.8: Genes and associated mutation types reported in lung cancer (Sung & 
Cho 2008; Altintas & Tothill 2013). 
 
Groups 
 
Types of genes 
 
Prevalence in sample 
Chromosomal 
changes 
Deletion of the short arm 
of chromosome 3 (3p) 
27-88 % in circulating DNA in 
lung cancer patients 
 
Hypermethylation 
 
Serine protease family 
member- 
trypsinogen IV (PRSS3) 
Tissue inhibitor of 
metalloproteinase 
(TIMP)-3 
Death associated protein 
(DAP)-kinase 
P16 
FHIT 
 
Associated with increased risk of 
lung cancer recurrence after 
therapy 
Genetic Changes 
KRAS 
 
P53 
 
20-30 % in circulating DNA of 
lung cancer patients 
27 % in circulating DNA of lung 
cancer patients 
 
1.16. Sources of Biomarkers 
Tumour markers can be detected in the blood, urine or serum in higher than normal 
ranges and may include; hormones, specific antigens, oncogenes and proteins, etc. 
(Altintas & Tothill 2013). The increased entry of these molecules into serum 
circulation is facilitated by mechanisms such as secretion, angiogenesis, invasion and 
destruction of tissue architecture (Prassas et al., 2012). 
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Plasma is a target of interest for biomarker detection as it would contain small 
amounts of circulating DNA fragments shed by normal and tumour cells undergoing 
apoptosis or necrosis (Herceg & Hainaut 2007). Serum tests for oncogene mutations 
and hyper-methylation of promoter regions are used for cancer detection. Since recent 
advances in genomic and proteomic technologies, specific changes in tumour cells 
expression levels can distinctly be measured, even with the presence of DNA shed by 
normal cells (Wulfkuhle et al. 2003). 
Recent studies into identifying sources of potential cancer markers has focused 
largely into secretome, which focuses on studies monitoring molecules shed from the 
surfaces of living cells, including proteins. Secreted molecules, proteins and 
extracellular matrix components from tumour cells are therefore a promising source 
of potential tumour markers (Makridakis & Vlahou 2010).  
In lung cancer specifically, serum, tissue and sputum serve as important sources of 
potential biomarkers. In sputum, cells from cancer sites are major protein sources. In 
biopsied lung tissue, cancer sites as well as cells involved in immune reactions such 
as, cytokines and derivatives from immune or inflammatory response can be found. 
In blood, however, biomarkers with potentially greater significance can be found 
(Saijo 2012). These include biomarkers found in biopsied cancer tissue as well as 
many circulating proteins and cells derived from the tumour tissue. Since the end goal 
of biomarker discovery is the specific, early and non-invasive diagnosis and post 
treatment monitoring of the disease, blood is thought of as an important biological 
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material. Resulting in many biomarker investigations carried out with blood based 
strategies (Sung & Cho 2008). 
Since many tumour markers exist in more significant concentrations in tumour tissue 
than in body fluids, biopsies still tend to be both invasive and uncomfortable for 
patients. Some genetic markers for lung cancer may be obtained from sputum or 
studying pleural fluid, but blood still appears to be a more suitable source for 
biomarkers (Altintas & Tothill 2013). 
When circulating RNAs are obtained from sputum, due to the high levels of 
ribonuclease (RNase) in the sputum, some of the total RNAs are degraded. 
Circulating nucleic acids is reported to be a crucial parameter for detecting the 
disease without invasiveness (Schwarzenbach et al. 2011). DNA and RNA molecules 
are present in the serum of both healthy and ill patients. The existence of circulating 
DNA in blood with malignant neoplasm has been known since the 1970s and since 
then researchers have attempted to develop methods using biological materials 
obtained from non-invasive procedures in order to locate potential biomarkers for 
early diagnosis (Altintas & Tothill 2013). 
1.17. Applications of Bioinformatics into Biomarker Discovery 
Bioinformatics is the application of computational techniques to analyse information 
associated with biological data on a large scale (Luscombe et al. 2001). There are 
three main aims in the field of bioinformatics. The first and most basic is to order 
data in such a way that users are able to access existing data as well as submit new 
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findings. The second, is to develop tools to assist in data analysis and the third, to use 
these tools to analyse and interpret results in such a way that they become 
biologically significant (Luscombe et al. 2001; Wu et al. 2012;). 
Biological studies have traditionally intricately examined isolated systems and often 
compared them to a few related studies. Bioinformatics in contrast, allows for the 
global analyses of data, aiming to uncover novel features and highlighting principles 
which apply to various disciplines (Luscombe et al. 2001). 
The major advancements achieved in unraveling the molecular mechanisms of human 
diseases, molecular diagnostics and therapy over the past two decades, is largely due 
to the substantial growth in the amount of genomic, proteomic and transcriptomic 
data being generated (Phan et al. 2009). 
As of August 2000, a repository of 8 214 000 nucleic acid sequences and 88 166 
protein sequences were publicly available, with datasets doubling in size every 15 
months (Luscombe et al. 2001). Since the publication of the Haemophilus influenzae 
(H. influenzae) genome, complete sequences for over 40 organisms have been 
released, ranging from 450 to over 100 000 genes (Fleischmann et al. 1995). This 
surge in data availability, coupled with a myriad of related studies; into gene 
expression, protein structure and interactions between various biomolecules resulted 
in many of these previously known biological challenges becoming challenges of 
computing. Thus firmly establishing bioinformatics as a discipline in molecular 
biology (Luscombe et al. 2001). 
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Gene expression levels can be determined by measuring mRNA levels with various 
techniques such as microarrays, expressed complementary DNA (cDNA) sequence 
tag (EST) sequencing, serial analysis of gene expression (SAGE) tag sequencing, 
massively parallel signature sequencing (MPSS) etc. (Raza 2012). These techniques 
have allowed an unbiased overview of changes occurring at transcriptional levels and 
have revolutionised cancer research, resulting in numerous potential biomarkers 
being generated (Rhodes & Chinnaiyan 2004; Werner 2008). 
Protein expression is one of the most accurate indicators of actual gene activity since 
proteins are usually final catalysts of cell activity. Protein microarrays and high-
throughput (HT) mass spectrometry (MS) can provide an image of the proteins 
present in a biological sample. Bioinformatics is integral in making sense of protein 
microarray and high throughput data (Raza 2012). 
1.18. Biomarker Validation 
Before biomarkers can be utilized in clinical practice, each biomarker needs to be 
discovered and validated by means of a process involving several important steps 
(Figure 1.8). The first step of this process consists of experimental design and data 
acquisition, generally in the form of large amounts of genomic or proteomic 
expression data (Prassas et al. 2012). Once acquired, data needs to be organised and 
annotated, this can be done using various databases and web based tools. The next 
stage in data processing is identifying candidate biomarkers, which are differentially 
expressed (DE), using classification methods and feature extraction. Functional 
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relevance of candidate biomarkers needs to then be evaluated by determining their 
biological expression level (Phan et al. 2009). Validation of these markers for 
example by means of real-time polymerase chain reaction (RT-PCR) and enzyme-
linked, immunosorbent assays (ELISAs) can be both labour and resource intensive, 
making validation of these markers of critical importance (Rhodes & Chinnaiyan 
2004). Given the necessity for disease specific biomarkers along with the flood of 
genomic and proteomic data, it is therefore, up to biological computation systems to 
provide methods to evaluate, integrate and translate the data (Kim et al. 2007). 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Biocomputing tools for discovery and validation of biomarkers (Phan 
et al. 2009). 
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1.19. Aims and Objectives 
Lung cancer remains the leading cause of cancer deaths worldwide. The efficiency of 
current treatment depends strongly on the time of diagnosis, at the time of diagnosis, 
the progression of the cancer is an important factor used to determine a treatment 
protocol as well as prognosis (Risch & Plass 2008). Current diagnostic techniques do 
not allow for early stage diagnosis, or detection of lung cancer in asymptotic patients, 
ultimately resulting in disease progression and a poor prognosis.  
This project aims to identify potential circulatory biomarkers only in Stage I and II 
lung cancer as possible diagnostic agents by: 
 Data mining public cancer databases for novel genes related to mechanisms 
involved in the stages and grades of the disease 
 Analysing microarray data using gene-set enrichment analysis (GSEA) techniques 
 Analysing RNA sequencing (RNAseq) data using bioinformatics enrichment tools 
 Correlating differentially expressed genes (DEG) between samples of:    
 - Early stage lung cancer vs. normal lung tissue and  
- Early stage disease vs. late stage lung carcinoma  
 Identifying co-expression of genes involved in the pathogenic phenotype 
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Chapter 2 
Identification of Potential Circulatory Biomarkers using Microarray Data 
2.1. Introduction 
The development of high-throughput technologies such as microarrays and Serial 
Analysis Gene Expression (SAGE) has led to a flood of cancer gene expression 
profiling data in the public domain (Gellert et al. 2010). Due to the large volume 
of data being generated, sifting through this data has become near impossible for 
the laboratory researcher. As a result, bioinformatics tools are used to provide 
methods to evaluate, integrate and translate the data (Rhodes & Chinnaiyan 2004). 
Thus, these information management systems aid in storing, extracting, 
organising, analyzing, interpreting and utilizing information from biological 
sequences and molecules (Luscombe et al. 2001). 
2.2. Data Mining 
The process of extracting or “mining” information from large amounts of data 
requires the application of specific algorithms for discovering novel correlations, 
trends and patterns from large amounts of data stored in computational 
warehouses (Fayyad et al. 1996; Raza 2012). Data mining is also often referred to 
as Knowledge Discovery in Databases (KDD) (Raza 2012). Although more 
accurately KDD (Figure 2.1) refers to the overall process of discovering useful 
knowledge from data, while data mining refers to a particular step in this process 
(Fayyad et al. 1996). 
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Data mining approaches are ideally suited for bioinformatics, due to data being 
collected and accumulated across a variety of fields at a rapid pace (Fayyad et al. 
1996). Moreover, the mining of biological data assists in extracting useful 
knowledge from large datasets. Many applications of data mining include; gene 
finding, protein function domain detection, protein and gene interactions, disease 
diagnosis, disease prognosis and disease treatment optimization, to name a few 
(Raza 2012). 
Post the evolution of microarrays and large scale databases of SAGE and 
expressed sequence tags (EST), bioinformatics tools can be used to integrate this 
public data in the search for potential biomarkers (Kim et al. 2007). 
Figure 2.4: Steps involved in knowledge discovery (Fayyed et al. 1996). 
2.2.1. Microarray Data Mining 
Advances in DNA microarrays have revolutionized cancer research, resulting in 
numerous gene expression profiling studies and generating a number of potential 
biomarkers (Rhodes & Chinnaiyan 2004). Expression profiling allows for the 
simultaneous measurement of cellular concentration of different mRNAs (Guo et 
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al. 2013), in which these tissue and serum markers are reported to have the 
potential to aid in more accurate diagnosis, prognosis as well as the potential early 
diagnosis of the cancer and the effectiveness of therapy (Rhodes & Chinnaiyan 
2004). 
Microarrays, also known as gene chips, quantitatively measure relative expressed 
mRNA levels between different samples (Luscombe et al. 2001). Expression data 
measured using microarray technology arise from a single, large experiment in 
which a collection of gene standards are always included in order to normalize 
experimental data (Munoz et al. 2004).  
At the beginning of the microarray era, bioinformatics tools were focused on 
unsupervised clustering, aiming to discover novel properties of data structure. 
More recently however, the interest of analysis of data has shifted to more 
supervised and guided analysis, focusing on differentially expressed genes (DEG) 
under various known conditions (Phan et al. 2009). 
Lists of candidate biomarkers generated from microarray data analysis depend on 
both the availability of samples as well as selection algorithms. High-throughput 
(HT) assay platforms are typically comprised of thousands of genes, making the 
interpretation of their results a daunting task. The association of candidate genes 
with biological functions aids in the process of understanding underlying 
mechanisms of the relevant disease and the biological relevance of the feature 
selection algorithm. Subsequently, Gene Ontology (GO) is used to facilitate 
interpretations of gene functions on a large scale (Phan et al. 2009). 
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2.2.2. Digital Expression Profiling using EST and SAGE 
The estimation of protein expression levels remains a significant area of interest in 
both genomics and proteomics. Protein expression levels indicate links between 
the genetics and an organism’s functional property, with average levels of protein 
expression allowing environments within cells to be determined. Changes in these 
levels can provide information regarding; developmental biology, stress-response 
and progression of disease (Munoz et al. 2004). 
Large scale sequencing of cDNAs provides a complementary approach to 
structural analysis of the human genome by generating ESTs (Okubuku, et al., 
1992). These fragments of mRNA sequences are derived through single 
sequencing reactions performed on randomly selected clones from cDNA 
libraries. Currently over 45 million ESTs have been generated from over 1 400 
different species of eukaryotes. EST projects are generally used to complement 
existing genome projects or serve as low-cost alternatives for gene discovery 
(Parkinson & Blaxter 2009).  
Unlike microarray studies which pools data from one large experiment, ESTs 
arise from the entire database, which is constructed from various experiments 
performed under different conditions which often examine different subsets of 
genes of interest (Munoz et al. 2004). 
Consequently, gene expression levels can be determined by measuring mRNA 
levels using expressed cDNA sequence tag sequencing and SAGE tag sequencing 
(Raza 2012). 
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SAGE is a method of obtaining quantitative absolute gene expression profiles 
from cells under selected physiological conditions (Margulies & Innis 2000; 
Luscombe et al. 2001). Unlike arrays, SAGE does not require any prior 
knowledge of genes to be analyzed (Hu & Polyak 2006). In the original EST 
approach, tags are 100 - 300 nucleotides in length. SAGE, however only requires 
9 nucleotides, therefore, allowing for a larger throughput (Audic & Claverie 
1997). 
2.3. Biological Databases 
Databases are ordered collections of data, generally stored in one or more 
associated files. The data is stored in tables, allowing cross referencing between 
them, with existing relationships among these tables producing a relational 
database (Niland & Rouse 2010). 
2.3.1. Oncomine 
Oncomine (http://www.oncomine.org) is a public cancer microarray database and 
web-based data-mining platform. Its primary aim is to facilitate discovery from 
genome-wide expression analyses (Rhodes et al. 2004). Oncomine incorporates 
65 gene expression datasets consisting of approximately 50 million gene 
expression measurements from over 4 700 microarray studies (Rhodes & 
Chinnaiyan 2004). Differential analyses in Oncomine compares cancer tissues 
with their respective normal type (Rhodes et al. 2004). Genes most under- and 
overexpressed are defined by over 100 differential expression analyses in nearly 
every major cancer as well as various clinical and pathology based subtypes 
(Rhodes & Chinnaiyan 2004). 
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2.3.2. Gene Expression Atlas  
The Gene Expression Atlas (GEA) (www.ebi.ac.uk/gxa/) launched by the 
European Bioinformatics Institute (EBI) is a public database which allows users 
to query gene expression under various biological conditions, including different 
cell types, developmental stages, physiological states, phenotypes and disease 
states. GEA content is derived from curation and statistical analysis of selected 
data from the ArrayExpress Archive of Functional Genomics Data (Kapushesky et 
al. 2009). To date, GEA contains data from over 200 000 genes of 9 different 
species and over 1 000 different independent studies, with the database being 
updated on a monthly basis (Kapushesky et al. 2009). 
2.3.3. Integrative OncoGenomics 
Integrative OncoGenomics (IntOGen)(http://www.intogen.org/) is a web platform, 
which provides support to researchers and aids in identifying tumour drivers in 
various cohorts. IntOGen identifies and visualizes cancer drivers, analyzing 4 623 
exomes from 13 cancer sites. Somatic mutations, genes and pathways involved in 
cancer have been summarized and made available for public curation (Gundem & 
Perez-Llamas 2010; Gonzalez-Perez & Perez-Llamas 2013). 
2.3.4. C-It 
C-It (http://c-It.mpi-bn.mpg.de) is a knowledge database that focuses on genes 
previously uncharacterised. The database contains expression profiles of various 
tissues, including human, mouse, rat, chicken and zebrafish. C-It is designed to 
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provide a comprehensive coverage of gene expression patterns and tissue-enriched 
splicing isoforms (Gellert et al. 2010). 
Included in the C-It database is literature information from PubMed, assisting in 
the identification of genes lacking publication records. Tissue expression data of 
ESTs are used to identify tissue-enriched genes and microarray and SAGE data 
provide comprehensive transcriptional profiles (Gellert et al. 2009; Gellert et al. 
2010). 
2.3.5. Tissue-specific Gene Expression and Regulation  
Tissue-specific Gene Expression and Regulation (TiGER) 
(http://bioinfo.wilmer.jhu.edu/) is a publicly available database which provides 
large scale data sets for tissue-specific gene (TSG) expression and regulation in 
various human tissues. The database includes three types of data, namely; tissue-
specific gene expression profiles, combinatorial gene regulations, and cis-
regulatory module (CRM) detections. TiGER currently contains expression 
profiles for 19 526 UniGene genes, combinatorial regulations for 7 341 
transcription factor pairs and 6 232 putative CRMs for 2 130 reference sequencing 
(RefSeq) genes (Liu et al. 2008). 
2.3.6. VeryGene 
VeryGene (http://www.verygene.com/) is a knowledge database of tissue-specific 
genes. The VeryGene web platform integrates TSGs from large-scale data 
analyses with respective information on subcellular localization, GO, Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway, Mouse Genome 
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Informatics (MGI) Mammalian Phenotype, disease association, and targeting 
drugs. The database presently consists of 3 960 annotated TSGs derived from 127 
normal human tissues and cell types, including 5 672 gene-disease and 2 171 
drug-target relationships (Yang et al. 2011). 
2.3.7. Database for Annotation, Visualization and Integrated Discovery 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/) is a HT knowledge platform which aims to provide 
a functional interpretation of large gene lists derived from genomic studies. The 
database integrates a multitude of public bioinformatics resources to combine tens 
of millions of diverse gene/protein identifiers and annotation terms from a variety 
of public bioinformatics databases (Huang et al. 2007). The grouping of 
identifiers improves cross-reference capability, enabling more than 40 publicly 
available functional annotation sources to be comprehensively integrated and 
utilized by the DAVID gene clusters (Sherman et al. 2007). 
DAVID is able to provide GO analysis, as well as condense large gene lists into 
gene functional groups and convert between gene/protein identifiers. By mapping 
genes to GO terms and then statistically highlighting the most enriched, increases 
the likelihood that the biological process of interest will be identified (Huang et al. 
2007). 
2.4. Text Mining 
Scientific literature represents a rich source for knowledge retrieval on 
associations between biomedical concepts such as genes, diseases and cellular 
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processes (Frijters et al. 2010). Biomedical text mining allows researchers to 
identify relevant information more accurately. Text mining facilitates 
establishment of relationships hidden within large amounts of available 
biomedical data currently in literature. It moves the burden of information 
overload from the researcher to the computer by the application of algorithmic, 
statistical and data analysis methods with (Cohen 2005) with various databases 
existing and facilitate text mining. 
2.4.1. Text Mining Databases 
2.4.1.1. The Universal Protein Knowledgebase  
The Universal Protein Knowledgebase (UniProtKB) provides a comprehensive 
resource for protein sequences and functional information. UniProtKB 
(http://www.uniprot.org) consists of two sections, UniProtKB/Swiss-Prot and 
UniProtKB/TrEMBL. UniProtKB/Swiss-Prot contains manually annotated 
records with information extracted from literature and computational analysis. 
The annotation consists of; function, enzyme-specific information, biologically 
relevant domains and sites, post-translational modifications, sub-cellular location, 
tissue specificity, developmental specific expression, structure, interaction and 
associated diseases, deficiencies or abnormalities (The UniProt Consortium 2010).  
2.4.1.2. PolySearch 
PolySearch (http://wishart.biology.ualberta.ca/polysearch) is a public web tool, 
specifically designed for extracting and analyzing text-derived relationships 
between human diseases, genes/proteins, mutations, drugs, metabolites, pathways, 
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tissues, organs and sub-cellular localizations (Liu 2013). PolySearch extracts and 
analyses not only PubMed data, but also text data from multiple databases 
(DrugBank, SwissProt, HGMD, Entrez SNP, etc.). PolySearch utilizes various 
techniques in text mining and information retrieval to identify, highlight and rank 
informative abstracts, paragraphs or sentences (Cheng et al. 2008). 
2.4.1.3. Human Genome Epidemiology Network  
The Human Genome Epidemiology Network (HuGENet) 
(http://www.hugenavigator.net/) maintains a database of published, population-
based epidemiologic studies of human genes extracted from PubMed. The 
introduction of machine learning search strategies have reduced the labour intense 
manual curation and increased both the sensitivity and specificity of the screening 
(Yu et al. 2008). The database is updated weekly with articles newly added to 
PubMed and has to date indexed more than 30 000 articles, referenced more than 
3 000 genes and indexed nearly 2 000 disease terms article with Medical Subject 
Headings (MeSH) terms and gene information from the National Center for 
Bioinformatics (NCBI) Entrez Gene database (Yu et al. 2008; Yu et al. 2009). 
2.4.1.4. Google Scholar 
Google Scholar (https://scholar.google.co.za/) is a subset of the Google search 
engine, consisting of full-text journal articles, technical reports, preprints, theses, 
books, and other documents, including selected Web pages. Google Scholar 
encompasses a diverse range of topical areas, but is deemed to be strongest in the 
sciences. Google Scholar's index is obtained from a crawl of full-text journal 
content of both commercial and open source publishers. It retrieves document or 
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page matches based on the keywords searched and then organizes the results using 
a closely guarded relevance algorithm. Since much of Google Scholar's content 
comes from licensed commercial journal content, search results may reveal only 
an abstract and not full text articles (Vine 2006). 
Aims: 
1. Data mining of several cancer databases (as outlined above) for the 
extraction of potential circulating biomarkers for the early diagnosis of 
lung cancer  
2.  Refining the compiled genes, using literature mining tools to generate a 
candidate gene list 
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2.5. Materials and Methods 
 
Figure 2.5: Outline of the methodology for biomarker discovery. 
 
2.5.1. Extraction of Candidate Gene Biomarkers  
The purpose of the cancer biomarker discovery pipeline analysis was to retrieve 
genes which were differentially expressed (DE) in lung cancer in comparison to 
normal lung tissue and to combine and filter these genes into a feasible gene list. 
In addition to identify genes specific for potential biomarkers found in the 
circulatory system. A bioinformatics approach was used to integrate public cancer 
databases. 
In this study, six databases were mined to identify novel genes highly expressed in 
lung cancer. Querying multiple databases were used to help overcome the 
shortcomings which are associated with using only one methodology or a single 
data type (Prassas et al. 2012). Input parameters used were key words/phrases that 
Candidate list of genes 
Literature mining to cross reference gene lists against experimentally verified 
lung cancer genes 
Identification of cellular localization of gene products using DAVID 
Combination of datasets and elimination of overlapping genes 
Data mining of various  public cancer databases  
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allowed for the extraction of genes highly specific to lung cancer tissue e.g. < lung 
cancer>, <homo sapiens>, <differential analysis> etc. 
The bioinformatics pipeline was divided into two main sections: 
I. Data mining of publicly available databases (candidate and reference gene 
lists), and  
II. Literature mining of experimentally validated lung cancer-associated 
genes.  
The gene extraction pipeline was followed according to the protocol described by 
Prassas et al. (2012), for the identification of tissue-specific serological 
biomarkers. 
 2.5.1.1. Oncomine Database  
Oncomine was mined for differentially expressed genes in lung cancer with the 
following input query:  
 Analysis type: Differential analysis, cancer vs. normal  
 Cancer type: Lung cancer. 
 Data type: mRNA  
 Pathology subtype: Stage and grade type.  
All datasets containing both up and down-regulated genes with respect to lung 
cancer were extracted. 
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2.5.1.2. Gene Expression Atlas Database 
Differentially expressed genes were queried in GEA using the following input 
parameters: 
 All genes  
  Up/down in  
 Homo sapiens 
  Lung cancer  
GO terms relating to cellular components (CC) (e.g. cytoplasm, integral to plasma 
membrane) were used to further refine the list of differentially expressed genes 
retrieved. 
2.5.1.3. IntOGen Database 
The Integrative OncoGenomics database was searched for genes, which were 
shown to be mutated in lung cancer. <Lung> was selected as the cancer site query 
and all experiments were selected for retrieval with <all> genes/modules. 
2.5.1.4. C-It Database 
The C-It database was searched for genes/proteins enriched in lung tissue. The 
query was specified for human data only. The following literature information 
search parameters were selected: 
 Fewer than five publications in PubMed and  
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 Fewer than three publications with the MeSH. 
2.5.1.5. TiGER Database 
The TiGER database was mined for ESTs. <Lung> was selected under Tissue 
View for the acquisition of relevant genes. 
2.5.1.6. VeryGene Database 
VeryGene was searched using Tissue View for human lung tissue 
specific/enriched genes. 
2.5.1.7. Excluded Databases 
Datasets from BioGPS (http://biogps.org/) and the Cancer Genome 
Characterization Initiative (CGAP) (http://cgap.nci.nih.gov/) were excluded, as 
the databases contained no available data on lung cancer. 
2.5.2. Analysis of Gene Lists 
The candidate gene list consisting of 12 combined datasets was submitted to 
DAVID Version 6.7 (http://david.abcc.ncifcrf.gov/) for Gene Enrichment 
analysis, with all duplicated genes deleted prior to submission. 
2.5.2.1. Functional Characterization using DAVID 
All datasets were submitted to DAVID for clustering and functional annotation by 
means of a 3 step process: 
Step 1. Uploading Gene List of Interest 
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"Start Analysis" was selected and subsequently the candidate gene list was 
uploaded. "OFFICIAL_GENE_SYMBOL " was chosen as the identifier of choice 
and "gene list" for viewing purposes. 
Step 2. Analysis of Candidate Genes 
The uploaded gene list was analysed using, "Functional Annotation Clustering", 
selected from DAVID's functional annotation tools. Class stringency was set to 
medium, with the following selected: display, fold change and Bonferoni 
Analysis. The dataset was then rerun using the newly selected options. 
Step 3. Annotational Clustering of Genes 
GO terms were used to select annotation clusters. Since the Cellular Component 
was the GO term of interest, clusters were queried using the following terms: 
 cell surface 
 secreted, 
 secretory granules 
 extracellular matrix 
 extracellular space 
 extracellular membrane.  
A sub-list of the newly acquired genes was created, exported and saved. 
2.5.3. Literature Mining of the Candidate Entities 
Literature mining was used to eliminate genes already experimentally linked to 
lung cancer, in an attempt to ensure that genes selected as potential biomarkers 
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would be novel. The databases used were: Uniprot, Polysearch, Google Scholar 
and HuGENavigator. 
Genes were searched for by entering the gene name with the Boolean term 
“AND” and the cancer of interest e.g. <lung cancer> AND <gene name>. All 
relevant literature, abstracts and journal articles, were searched for information 
linking the genes as biomarkers for lung cancer. All genes found to be 
experimentally validated or suggested as lung cancer biomarkers were eliminated 
and a final candidate gene list was subsequently created. 
2.6. Results and Discussion 
2.6.1. Identification of Eligible Cancer Biomarkers 
The methodology of mining several cancer databases was used to identify DE 
genes that encode proteins secreted into bodily fluids with potential application as 
biomarkers of early diagnosis in lung cancer. Genes are usually considered as 
potential targets or markers if they are highly over expressed in a particular type 
of cancer (Rhodes et al. 2004). 
For each database utilized, specific criteria, tools and data mining steps were used 
to increase stringency and reduce the volume of data retrieved. All queries into 
respective databases followed the protocols as outlined in 2.5.1.1 to 2.5.1.7. 
Mining of the Oncomine microarray database for genes differentially expressed in 
lung cancer in comparison with normal lung tissue resulted in the identification of 
590 genes. Genes were ranked-ordered by the p-value and seed lists of the top 1 
%, 5 % and 10 % relative expression were retrieved resulting in a total of 6 output 
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gene lists. Datasets were categorized based on the different levels of gene 
expression as compared to its normal counterpart (Table 2.1.). A total of 1 749 DE 
genes were retrieved from Oncomine, and subsequent combining of all seed lists 
and eliminating duplicates, 1 159 genes remained. 
Table 2.9: Summary of genes extracted from Oncomine. 
Relative expression compared to 
normal tissue counterpart 
Number of genes extracted 
1 % 122 
5 % 547 
10 % 1 080 
 
GEA is a database consisting of high quality microarray experimental data. 
Querying this platform searched for genes up or down regulated in lung cancer 
tissue and included CC GO terms that generated 25 039 genes (Table 2.2.). The 
use of GO annotation provided a platform for the discovery of potential markers 
that were up-regulated in cancers and are used to further filter analysis. Following 
curation of the list a total of 10 512 DE genes were formatted. 
Table 2.10: Summary of genes extracted from GEA based on GO terms. 
GO Term  Number of Genes 
Protein Binding 8 631 
Cytoplasm 4 961 
Nucleus 5 087 
Cytosol 2 594 
Integral to Membrane 3 766 
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GEA microarray data is sourced from ArrayExpress, a generic microarray 
database designed to hold data from all microarray platforms (Brazma et al. 
2003). Biological relevance is ensured by comparing expression in healthy and the 
relevant diseased tissue, maintaining a minimum of 3 sample replicates and 
providing both p-values and t-statistics for all microarray analyses (Petryszak et 
al. 2014) IntOGen is a platform which displays somatic mutations identified in 
various cancers. Copy number changes and changes in gene expression were used 
to identify cancer drivers in the tissue of choice (Gonzalez-Perez et al. 2013). 
Mining the IntOGen database initially produced 53 466 genes, but elimination of 
duplicate genes resulted in 2 934 unique genes (Table 2.3). 
C-It, VeryGene and TiGER are databases containing tissue specific enriched 
genes. C-It focused on uncharacterised tissue-enriched gene variants and TSGs, 
and generated 1 819 unique genes. While TiGER and VeryGene are both based on 
ESTs, each had a unique data output of 117 and 92 genes, respectively. Even 
though databases are based on similar sources of data, individual databases still 
identified unique outputs, further validating the initial approach of mining several 
databases (Table 2.3). 
Table 2.11: Summary of genes extracted from databases. 
 
Database 
 
# Genes Identified 
 
# Duplicated 
Genes 
 
# Unique Genes 
Oncomine 1 749 590 1 159 
GEA 25 039 14 527 10 512 
IntOGen 53 466 50 532 2 934 
C-It 2 708 889 1 819 
TiGER 156 39 117 
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VeryGene 94 2 92 
Total Number of 
Combined 
Genes 
83 212 66 579 16 633 
 
2.6.2. Gene Enrichment Analysis 
DAVID allows for the extraction of biological meaning from large gene or protein 
lists by using text and pathway mining tools (Huang et al. 2007). A total of 16 633 
genes were uploaded to DAVID for gene enrichment analysis with a resultant 
output of 117 genes generated. 
Enrichment analyses of GO terms: biological process (BP), cellular component 
(CC) and molecular function (MF) was performed on the 117 genes using the 
functional clustering annotation tools. 
GO is a set vocabulary as stipulated by NCBI, applied to the functions of genes 
and proteins (Dennis et al. 2003).  
Statistical significance of GO terms was analysed using the p-values (<0.05) and 
false discovery rate (FDR <0.05), which corresponds to a 95 % confidence of 
enrichment. Default options of medium/high classification stringency were used, 
and cluster names were extracted from the most biologically relevant GO term 
assigned to each cluster. 
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Figure 2.6: Functional characterisation of genes in DAVID based on their biological process using GO analysis. 
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Figure 2.7: Functional characterisation of genes in DAVID based on their cellular component using GO analysis. 
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Figure 2.8: Functional characterisation of genes in DAVID based on their molecular function using GO analysis. 
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2.6.3. Literature Mining of Candidate Genes 
Following functional clustering and GO annotation in DAVID, the list 117 genes 
were investigated using literature mining, in order to obtain a subset of genes of 
greater relevance to be validated as novel potential biomarkers for lung cancer. 
Text mining was performed using the following databases; Uniprot, PolySearch, 
Google Scholar and HuGENavigator. All cited literature; articles, abstracts and 
references linked to genes of interest were carefully scrutinized. Genes not yet 
experimentally validated as having any involvement in lung cancer were chosen 
for the new subset of candidate genes. Of the 16 633 genes queried in DAVID, 
only 117 genes met the criteria selected for this study. Literature mining further 
reduced this number to 20 candidate genes not experimentally linked to lung 
cancer. Further curation of these 20 candidate genes was performed by literature 
mining using the same databases. All genes found to be experimentally validated 
or linked to any other cancer was eliminated to further increase the stringency, 
resulting in a list of 4 candidate markers: 
 COPZ1 (Coatomer Protein Complex, Subunit Zeta 1) 
 SEC23B (S. Cerevisiae Homolog B) 
 SEC24A (S. Cerevisiae Family Member A) 
 SEC24D (S. Cerevisiae Family Member D) 
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2.7. Discussion and Conclusion 
Lung cancer remains a serious health burden and the leading cause of cancer 
related deaths globally. A good prognosis as well as efficiency of treatment 
strongly depend on early stage diagnosis of the cancer (Risch & Plass 2008). 
However, most tumours are diagnosed at a late stage, presenting with distant 
metastasis. There is no validated screening method for lung cancer and the overall 
five-year survival rate of less than 10 % has not changed significantly in the last 
20 years. There is therefore, a need for an early, rapid detection method which is 
both non-invasive and cost efficient (Brambilla et al. 2003).  
Lung carcinogenesis is a multistep process involving the accumulation of genetic 
and epigenetic mutations. Much of what is known about the biological pathways 
and processes in tumorigenesis is derived from the investigation of genes and their 
functions (Stratton et al. 2009). Many genetic alterations which occur during 
tumour development disrupt paracrine signaling networks, resulting in the release 
of cancer cells from regular growth constraints. Cancer specific autocrine and 
paracrine signals is often accompanied by the inappropriate expression of secreted 
proteins or their receptors (Welsh et al. 2003). 
Increasing evidence that the interaction and network between genes and proteins 
play a pivotal role in the understanding of the molecular mechanism of cancer has 
resulted in a systems approach to the study of this disease. The concept of systems 
biology into cancer research, integrates omics-based technology, clinical science, 
molecular biology, bioinformatics and computer science to aid in diagnosis, 
therapies and prognosis (Wu et al. 2012). 
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Cancer bioinformatics presents an essential tool to the process of early diagnoses 
and has the potential to play a critical role in the identification and validation of 
biomarkers, specific to clinical phenotypes (Chen et al. 2013). 
Circulatory biomarkers would represent a non-invasive aid in the clinical 
management of cancer patients, particularly in areas of disease diagnosis, 
prognosis, monitoring and therapeutic stratification (Chi-Shing Cho 2007). The 
marker needs to be produced by the tumor or its microenvironment and enter the 
circulation, resulting in increased serum levels. For a serological biomarker to be 
ideal for early detection, its presence in serum must be low in healthy individuals. 
The mechanisms which facilitate the entry into circulation include secretion or 
shedding, angiogenesis, invasion and destruction of tissue architecture (Altintas & 
Tothill 2013). The biomarker would also need to be tissue specific such that a 
change in serum level can be directly attributed to lung cancer. 
In this study, several in silico approaches were used to investigate high-
throughput databases. Microarray platforms were queried and various 
bioinformatics tools were used to identify genes encoding secreted proteins in 
human lung cancer. Lists of candidate biomarkers generated from microarray data 
analysis depend on sample availability as well as the respective selection 
algorithm. These lists may often vary from sample to sample or be highly unstable 
(Phan et al. 2009). When investigating gene databases for this analysis, stringency 
was set to high for all platforms, so as to filter the number of genes generated to a 
more specific group of interest. 
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Data generated from these platforms typically consists of tens of thousands of 
genes, making interpretation of their results a daunting task. The association of 
candidate genes with biological functions, assists in understanding underlying 
mechanisms of the associated disease as well as relevance of feature selection 
algorithms (Harris et al. 2004).The gene-annotation enrichment analysis (HT 
strategy) increased the likelihood of identification of biological processes most 
relevant to the specific study. Bioinformatics methods, using GO allowed for the 
systematic dissection of large gene lists in an attempt to assemble a summary of 
the most enriched and pertinent candidates (Huang et al. 2009). 
GO collected biological knowledge in a gene-to-annotation format, suitable for 
HT bioinformatics scanning for enrichment analysis. The tools allowed for 
systematic mapping of large lists of genes of interest, associated with biological 
annotation terms (GO Terms), which then statistically examined the enrichment of 
gene members for each of the annotation terms by comparing the outcome to the 
control (Smith et al. 2003; Huang et al. 2009).  
The GO covers 3 domains: (1) MF, which describes activities, such as catalytic or 
binding activities, and represent activities rather than the molecules or complexes 
performing the actions It does not specify where, when or in what context the 
action takes place. (2) BP describes the biological goals achieved by one or more 
ordered assemblies of molecular functions and can be used to describe processes 
such as apoptosis or chromatin condensation. (3) CC describes the sub-cellular 
structures and macromolecular complexes locations (Harris et al. 2004) 
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GO cellular component annotations (Figure 2.4.) were of most relevance to this 
analysis as it allowed for grouping according to mechanisms that facilitate 
biomarker entry into the circulation (Huang et al. 2007). Significance of these 
terms is given by their assigned p-values, which denotes the probability of a term 
occurring in the set by chance or not. This GO enrichment analysis with very high 
significance (p < 0.05), represents a set of genes highly similar in its properties. 
The methodological approaches previously described resulted in the identification 
of 16 633 genes found to be highly expressed in lung cancer tissue. Further 
enrichment analysis in DAVID through annotation and sequence analysis-based 
approaches, generated 117 candidate genes. 
GO analysis of these genes showed the majority were enriched for CC (intrinsic 
and integral to membrane and cell surface) (Figure 2.4.). These results proved 
promising since the targeted biomarkers for this subsection of the study were 
those, which would be easily detectable in bodily fluids. Results of MF (Figure 
2.5.) were consistent with BP (Figure 2.3.) showing a large majority of the genes 
to be involved in membrane trafficking, transport and localization. 
The strategy of mining gene and protein databases was described by Prassas and 
colleagues (2012). Mining of databases for proteins highly specific to or strongly 
expressed in a specific tissue, selects proteins which are secreted or shed to 
prioritize candidates for further validation (Prassas et al. 2012). Even though 
proteomics provides a more functional approach than genomics, proteomics alone 
might be insufficient as post-translational modifications, such as phosphorylation, 
control the stability and function of many proteins (Welsh et al. 2003). Mining 
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both gene and protein platforms with different data sources (ESTs and 
microarrays) aimed to minimize the limitations of each resulting in the 
identification of more specific markers (Prassas et al. 2012). 
Literature mining was used to further reduce the generated list of candidate 
markers. These genes/protein have been well studied but not as potential cancer 
biomarkers and thus represent potential candidates. The emphasis of this study 
was to identify novel candidates, which have not been experimentally linked or 
validated in lung cancer or any other mechanisms of carcinogenesis. 
This in silico analysis identified four genes; SEC 23B, SEC 24A, SEC 24D and 
COPZ1, pending validation, as early diagnostic biomarkers for lung cancer. 
Laboratory based validation of data would provide independent, experimental 
validation of gene expression levels. There are several molecular methodologies 
available to validate these results such as, RT–PCR, northern blot, RNase 
protection assay, and in situ hybridization or immunohistochemistry using tissue 
microarrays (Chuaqui et al. 2002). More specifically, real-time RT–PCR, which 
quantitatively measures specific mRNAs could be used to validate expression 
patterns. These genes identified in silico will be linked to specific cell function in 
Chapter 4 and compared to the genes filtered for Next Generation Sequencing 
(NGS) (Chapter 3). 
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Chapter 3 
Identification of Potential Circulatory Biomarkers using RNAseq Data 
3.1. Introduction 
Cancer presents in various forms depending on; the location, cell of origin as well 
as the range of genomic alterations, which promote oncogenesis. Many genomic 
events with direct phenotypic correlation have been identified, yet the complex 
molecular landscapes remain uncharted for many cancer lineages (Chang et al. 
2013). The inception of gene expression microarrays led to the possibility of 
genomic phenotype classification. Fundamentally however, two major problems 
have hindered this endeavour: (1) the inaccuracy of microarray measurements and 
(2) small sample sizes (Knight et al. 2014). Improvements in sequencing and 
array-based profiling have resulted in an influx of diverse genome related data, 
including whole genome sequencing and exome based data, with expression 
profiling of both coding and non-coding RNAs and SNPs (Robinson et al. 2011; 
Guo et al. 2013). Analysis of these large, diverse datasets holds the potential for a 
comprehensive understanding of the human genome and its relation to disease 
(Robinson et al. 2011). 
3.2. Next Generation Sequencing  
Next Generation Sequencing (NGS), also known as massively parallel signature 
sequencing (MPSS) has revolutionised the characterisation of cancer at the 
genomic, transcriptomic and epigenetic levels. This technology has allowed for 
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cataloguing of mutations, copy number aberrations and somatic rearrangements in 
an entire cancer genome at base pair resolution (Reis-Filho 2009). NGS can 
provide unbiased transcriptomic analysis of mRNAs, small RNAs and non-coding 
RNAs, genome-wide methylation assays and high throughput (HT) chromatin 
immuno-precipitation assays (Reis-Filho 2009). Whole genome sequencing 
allows a deeper understanding into the full spectrum of genetic variation as well 
as phenotypic variation and pathogenesis (Mamanova et al. 2010). 
3.2.1. RNA Sequencing  
The introduction of RNA Sequencing (RNAseq) has revolutionised expression 
research. It refers to the use of NGS technologies to sequence cDNA to obtain 
information about the respective sample’s RNA content (Guo et al. 2013). 
RNAseq allows for complete sequencing of transcriptomes in almost any tissue or 
population and is often used to measure gene expression (Davey et al. 2011). 
RNAseq technologies sequence small mRNA fragments to measure gene 
expression and is viewed as the transcriptome analog to whole genome shotgun 
sequencing (Li et al. 2010; Knight et al. 2014). However, RNAseq is primarily 
used to estimate the copy number of transcripts in a sample (Li et al. 2010). 
During a standard RNAseq experiment, an RNA sample is converted to cDNA 
fragments and sequenced by a commercially available HT platform. Raw data 
consists of large amounts of sequences of DNA fragments, called reads, that 
undergo a series of steps of analysis including; mapping the reads, summarizing 
each genes map counts, normalization and detection of differentially expressed 
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genes (DEG) (Oshlack et al. 2010; Kvam et al. 2012). Subsequently, gene 
expression is determined by measuring the number of reads mapped to a gene 
(Knight et al. 2014). RNAseq therefore provides a discrete measurement for gene 
expression, unlike fluorescence intensity measurements from microarray 
platforms. Consequently, new statistical methods are needed to appropriately 
handle the large volume of RNAseq data being generated (Kvam et al. 2012).  
Detection of DEG is often the end goal of statistical analysis of RNAseq data and 
aids in elucidating gene function (Robinson & Oshlack 2010). They can also serve 
as an initial step in gene expression clustering profiling or gene set enrichment 
(Kvam et al. 2012). Since the recent advent of RNAseq technologies and its 
continuous development, no standard methods have yet been determined to detect 
DEG based on the data (Oshlack et al. 2010; Kvam et al. 2012). 
In comparison to microarrays, the RNAseq method offers several advantages. The 
detection range of RNAseq is not limited to a set of predetermined probes as with 
microarray methods. RNAseq can detect expression at the gene, exon, transcript 
and coding DNA sequence (CDS) level while microarrays are limited to the gene 
level or the exon level for specially designed exon arrays. RNAseq is also able to 
detect structural variants such as alternative splicing and gene fusion (Guo et al. 
2013). 
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3.2.1.1. RNAseq Version 2 
RNASeq Version 2 (RNAseq V2) similarly to RNAseq uses mapped counts to 
determine gene expression levels, however a different set of algorithms are used 
to determine the expression levels (Li et al. 2010). Since the number of reads from 
a gene is a function of the length of the mRNA as well as its molar concentration, 
it is necessary to normalize the read count while preserving molarity (Pepke et al. 
2009). Two analysis pipelines are used to create and normalize Level 3 expression 
data from this data.  
The first approach relies on the Reads Per Kilobase of exon model per Million 
mapped reads (RPKM) method and is utilized in various databases such as The 
Cancer Genome Atlas (TCGA) (Li et al. 2010). RPKM quantifies gene expression 
from RNA sequencing data by normalizing for total read length and the number of 
sequencing reads, making them directly comparable within the sample (Mortazavi 
et al. 2008). The second method uses RNAseq by Expectation-Maximization 
(RSEM) for quantitation (Li et al. 2010). RPKM is most commonly used and is 
calculated using the formula: RPKM = 10
9
(C/NL), where C is the number of reads 
mapped to the gene, N is the total number of reads mapped to all genes and L 
represents the length of the gene (Guo et al. 2013). The key difference between 
RPKM and RSEM is that the normalization factor of RPKM is proportional to the 
mean length of a transcript unlike RSEM which is independent of the mean 
expressed transcript length (Guo et al. 2013; Li et al. 2010). 
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3.3. The Cancer Genome Atlas  
The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) is a public 
systematic cancer genomics project which applies emerging technologies to the 
analysis of specific tumour types (Chang et al. 2013).  TCGA was launched by the 
NCI and the National Human Genome Research Institute (NHGRI) with the goal 
of improving the ability to diagnose, treat and prevent cancer. TCGA provides 
molecular profiles at DNA, RNA, protein and epigenetic levels for various 
cancers and their subtypes as well as hundreds of clinical tumour samples (Chang 
et al. 2013).  
Samples are characterized using technologies that evaluate the sequence of the 
exome; copy number variation (measured by SNP arrays), DNA methylation, 
mRNA expression and sequence, miRNA expression and transcript splice 
variation. Whole-genome sequencing may also be applied to a subset of the 
tumors (Kandoth et al. 2013). As of July 2013, TCGA had molecularly mapped 
patterns across 7992 cases, which represented 27 different tumour types. TCGA 
aims to have analyzed the genomic, epigenomic and gene expression profiles of 
more than 10 000 specimens from over 25 various tumour types by the end of 
2015 (Chang et al. 2013). TCGA has currently archived 497 and 470 specimens 
from lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) 
biopsies, respectively. The datasets are composed of level 3 RNAseq V2 data 
which are mapped read counts against 20 531 known human RNA transcripts 
(Knight et al. 2014). 
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3.4. Bioinformatics Analysis Tools 
3.4.1. Bioinformatics Enrichment Tools 
Current enrichment tools are categorized into three classes; singular enrichment 
analysis (SEA), gene set enrichment analysis (GSEA), and modular enrichment 
analysis (MEA) based on their respective algorithms (Huang et al. 2009). SEA 
measures expression levels in each gene individually; MEA adopts this same 
enrichment calculation, while also incorporating a network discovery algorithm 
(Huang et al. 2009; Laukens et al. 2015). GSEA evaluates gene set data, 
considering expression profiles from samples belonging to the two 
aforementioned classes (Subramanian et al. 2005) and is commonly used in the 
analysis of differential expression data, providing greater statistical power 
compared to SEA methodologies (Draghici et al. 2007).  
Changes and regulation of genome-wide genes can be measured simultaneously 
using HT technologies. These approaches typically generate large gene or protein 
lists as their final output (Berriz et al. 2009; Huang et al. 2009). The challenge lies 
in translating these results within the context of their underlying biological 
mechanisms (Laukens et al. 2015). Bioinformatics enrichment approaches may 
facilitate identification of these pertinent processes and pathways (Subramanian et 
al. 2005). Biological processes involve several genes as opposed to a single gene 
alone, forming the foundation of enrichment analysis. If these mechanisms are 
altered or abnormal, co-functioning genes should have a greater potential to be 
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selected as a relevant group when analyzed (Huang et al. 2009). Enrichment tools 
query lists of DEG against prior knowledge gene-set libraries. Gene-set libraries 
organize and store functional knowledge, such as pathways and transcription 
factors of each gene in the group (Chen et al. 2013). Most of these analysis tools 
focus on mapping genes to associated biological annotation terms (e.g. GO or 
pathway) and then statistically compute enrichment (Draghici et al. 2007; Alaimo 
et al. 2015). Regardless of their specific features, three main layers can 
characterize all of these tools, namely; backend annotation database, or data 
support, data mining which includes algorithms and statistics, and result 
resentation (Figure 3.1) (Huang et al. 2009). 
 
 
 
Figure 3.1: The typical infrastructure of enrichment tools with three distinct 
layers: backend annotation database, data mining, and result presentation (Huang 
et al. 2009). 
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3.4.1.1. MultiExperiment Viewer  
MultiExperiment Viewer (MeV) is a java based free software application, which 
utilizes modern bioinformatics tools for integrative data analysis. MeV v4.9 
(http://tm4.org/mev.html) is a component of the TM4 Microarray Software Suite 
which incorporates sophisticated algorithms for clustering, visualization, 
classification, statistical analysis, and biological theme discovery from single or 
multiple experiments (Howe et al. 2010). 
Robust statistical methods and data analysis tools are imperative to users of 
RNAseq data. MeV allows users to load raw or normalized data and supplies a 
variety of algorithms for clustering, classification and statistical analysis (Saeed et 
al. 2006). Currently 24 analysis techniques are available in MeV. These 
algorithms are broadly categorized into three types based on the objectives they 
aim to accomplish, namely; exploratory techniques, hypothesis testing and 
classification (Howe et al. 2011).  
Once data is loaded MeV generates an expression matrix, which is a two-
dimensional array of expression elements from genes (Figure 3.2). Each row is an 
expression vector from a specific gene and each column corresponds to a given 
experiments expression vector. Typically low expression is indicated in green and 
high expression in red (Saeed et al. 2006).  
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Figure 3.2: Expression matrix displaying rows of genes with high (red) and low 
(green) expression in relation to samples in each column generated by MeV v4.9 
(http://tm4.org/mev.html). 
3.4.1.2. Enrichr 
Enrichr, (http://amp.pharm.mssm.edu/Enrichr/) is a HTML5 web-based, 
bioinformatics enrichment analysis application. This tool provides a novel 
approach to rank enriched terms and displays innovative, interactive visualizations 
of results. A total of 35 gene-set libraries are available, totaling 31 026 gene-sets, 
which encompass both the human and mouse genome and proteome. Each gene-
set consists of approximately 350 genes, with more than six million connections 
between genes and terms. Some libraries are incorporated from other tools or 
databases while many remain exclusive to Enrichr. Libraries are divided into six 
categories: transcription, pathways, ontologies, diseases/ drugs, cell types and 
miscellaneous (Chen et al. 2013). 
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The three ontology trees, namely biological process (BP), cellular component 
(CC) and molecular function (MF), supply gene-set libraries to the ontology 
category, while well-known pathway databases provide knowledge to Enrichr's 
pathway category, which include, BioCarta, Kyoto Encyclopedia of Genes and 
Genomes (KEGG), WikiPathways and Reactome. Gene-set libraries created from 
kinase enrichment analysis (KEA), unique to this platform are also in included in 
this category (Chen et al. 2013). The category of diseases/drugs incorporates 
libraries from the Connectivity Map database, the Gene Signatures Database 
(GeneSigDB), the Molecular Signatures Database (MSigDB), Online Mendelian 
Inheritance in Man (OMIM), and VirusMINT (Chen et al.  2013). 
Enrichment scores assess significance of overlap between the input genes and the 
tool’s available knowledge contained in the gene-set libraries. These evaluations 
include; p-values, z-score test statistics; and a combined score incorporating both 
of the former. With these features, Enrichr can be used to obtain a global view of 
cell regulation in cancer by comparing highly expressed genes in cancer tissues 
with their normal counterpart (Chen et al. 2013). 
3.4.2. Databases and Platforms 
3.4.2.1. Molecular Signatures Database 
The Molecular Signatures Database (MSigDB) v5.0 
(http://www.broadinstitute.org/msigdb) is a knowledge based repository 
containing over 6700 annotated gene sets (Liberzon et al. 2011). Developed and 
maintained by the Broad Institute to facilitate GSEA, incorporated tools allow for, 
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the computing of gene set overlaps, categorizing of gene families, and heat map 
visualization of expression profiles from referenced compendia (Liberzon 2014). 
MSigDB gene families include oncogenes, tumour suppressors, translocated 
cancer genes, transcription factors, protein kinases, homeodomain proteins, cell 
differentiation markers and cytokines/growth factors (Liberzon et al. 2011).  
3.4.2.2. Gene Expression Atlas  
Gene Expression Atlas (GEA) (www.ebi.ac.uk/gxa/) is an annotated database 
which provides gene and protein expression profiles from over 200 000 genes in 
various cell types, biological conditions, phenotypes and disease states 
(Kapushesky et al. 2009). The platform consist of high quality baseline and 
differential expression data obtained from microarray and RNAseq experiments 
(Petryszak et al. 2014). 
Aims: 
1. Collection of clinical LUAD samples and generation of RNAseq V2 Level 
3 data for each stage of the disease as well as its normal tissue counterpart 
2. Analysis of this data using bioinformatics feature selection and enrichment 
tools to identify relevant biological phenomena pertinent to the disease to 
aid in the development of early stage LUAD biomarkers 
This chapter focused only on clinical data of adenocarcinomas of the lung. Since 
although lung cancer in general remains a global burden, LUAD specifically has 
surpassed all other lung carcinoma types to become the most common histologic 
subtype of this pathology. While most incidences of the disease are related to 
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smoking, LUAD still develops more frequently than any other lung cancer type, 
particularly in females who have never smoked (Travis et al. 2004). 
3.5. Materials and Methods 
 
Figure 3.3: Methodological approach for the retrieval and analysis of lung 
adenocarcinoma RNAseq V2 Level 3 data from the Cancer Genome Atlas 
 
 
3.5.1. Data Retrieval from TCGA 
 
Clinical LUAD samples were collected from TCGAs Data Portal, via the Open-
Access HTTP Directory using the following pipeline; Lung adenocarcinoma 
(luad), bcr/biotab/clin/nationwidechildrens.org_clinical_patient_luad.txt. 
All data retrieved was filtered using TNM staging into three classes, normal (N), 
early (E) (Stage I & II) and late (L) (Stage III & IV) and uploaded to the Data 
Matrix using the following he following filters: 
Identification of up/down regulated genes using GSEA platforms 
Enrichment analysis using Enrichr 
Statistical analysis using MeV Array Viewer 
Generation of RNASeq V2 Level 3 data for each class using TCGA 
Staging (TNM): normal, early tumour (Stage I and II), late tumour (Stage III and IV) 
Data retrieval of clinical luad samples from TCGA 
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 Disease: Lung adenocarcinoma  
 Data type: RNASeq V2 
 Data level: 3 
 Access Tier: Public 
 Availability: Available data 
 Frozen preservation 
 Tumour/normal filters for the respective samples 
RNASeqV2 archives were built as the output of choice, and gene based 
normalised results saved for each respective sample. 
3.5.2. Analysis of Data using selected Bioinformatics Tools 
3.5.2.1. Analysis using MultiExperiment Viewer 
Data was uploaded to MeV Multiple Array Viewer from the File menu. The Tab 
delimited, Multiple Sample Files (TDMS) option was selected and the files of 
interest were uploaded. The upper-leftmost cell, containing an expression value 
was selected and the data was imported. Log 2 transform was selected under the 
Adjust data tab. The Cluster Manager tab was used to cluster samples as E, L and 
N, using previously outlined criteria to allow statistical analysis between samples. 
Changes in expression between samples, was determined by performing 
parametric t-Tests between unpaired samples. Three variations of this test were 
implemented, using different false discovery corrections (FDC) and p-value 
parameters, (Table 3.1) to determine p-values for each class (E vs. N, E vs. L, N 
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vs. E). Fold change (FC) was used as a complementary step to evaluate 
significance, with FC > 2 used to indicate relevance. Data sets of interest were 
selected as group 1 and 2 and significant genes were determined for each class. 
For each class, DEG were deemed significant to this study only if they were 
identified using all three FDC methods implemented (Table 3.1). Since this study 
aims to identify markers useful in early stage diagnosis, enriched genes in classes, 
E vs. N and E vs. L were selected for further investigation. 
Table 3.12: Statistical parameters implemented to identify DEG between LUAD 
N, E and L samples using MeV 
 t-Test 1 t-Test 2 t-Test 3 
p-value 
parameters 
p = 0.01 
based on t-
distribution 
p = 0.05 
based on t-
distribution 
p = 0.05 
based on permutation, 
randomly group: 100x 
p-value/ FDC 
Just alpha (α) no 
corrections 
Standard 
Bonferroni 
correction 
maxT, proportion of false 
genes not exceed 0.05 
Hierarchical 
clustering 
(HCL) 
Hierarchical trees 
for significant 
genes only 
Hierarchical trees 
for significant 
genes only 
Hierarchical trees for 
significant genes only 
HCLTree 
selection 
Gene tree 
Sample tree 
Gene tree 
Sample tree 
Gene tree 
Sample tree 
Ordering 
Optimization 
Gene leaf order, 
Sample leaf order 
Gene leaf order, 
Sample leaf order 
Gene leaf order, 
Sample leaf order 
 
3.5.2.2. Enrichment Analysis using Enrichr  
DEG identified in MeV, as statistically significant in classes E vs. N and E vs. L 
were further evaluated to determine whether they contained any commonality 
before conducting enrichment analysis. Any genes identified in both groups, were 
eliminated due to lack of specificity to early stage diagnoses. These genes would 
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be involved in both developmental stages of the cancer and not present the ideal 
early stage biomarker. The final, curated E vs. N gene list was then uploaded to 
Enrichr. Data generated from the gene-set libraries of; Pathways, Ontologies, and 
Diseases/Drugs were investigated using computed p-value, z-score and combined 
test statistics generated. Results were viewed as network visualizations and 
histograms to better understand interactions and putative mechanisms involved in 
each analysis. 
3.5.2.2.1. Ontology Annotation Sources 
The Gene Ontology (GO) (http://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz) 
provides functional descriptions of gene products in relation to their cellular 
location and involvement in biological processes and molecular functions.  
To identify genes likely to be secreted into the extracellular exome, and therefore 
serve as potential serum markers, CC GO terms of, extracellular space, 
extracellular region and extracellular exome were used. 
The Pathway Ontology (http://www.ncbi.nlm.nih.gov/pubmed/24499703) 
characterises biological pathways, including altered and disease pathways in 
relation to gene expression.  
The Disease Ontology (http://www.ncbi.nlm.nih.gov/pubmed/26093607) is a 
standardized vocabulary aimed at providing descriptions of human disease 
phenotype characteristics. 
The Human Phenotype Ontology 
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(http://www.ncbi.nlm.nih.gov/pubmed/22961259) aims to provide correlations 
between biological data in relation to disease and depicts human disease 
phenotypic features. 
The Mammalian Phenotype Ontology 
(http://www.ncbi.nlm.nih.gov/pubmed/24217912) allows for annotation of 
mammalian phenotypes in the context of genotypic variations and gene knockout 
models, and are used as models of human disease.  
3.5.3. Gene Expression Analysis  
3.5.3.1. Molecular Signatures Database 
Candidate gene lists (Table 3.4) (Table 3.5) were queried in MSigDB to evaluate 
genes both under and over expressed across a multitude of cancer cell lines. Genes 
were referenced using the NCI-60 cell lines National Cancer Institute referendum 
and expression data was generated from the categories of cancer gene 
neighbourhoods and oncogenic signatures, derived directly from gene expression 
cancer profiles.  
 
3.5.3.2. Gene Expression Atlas  
Genes of interest and those identified as potential serum markers, (Table 3.4) 
(Table 3.5) were uploaded to GEA and searched against homo sapiens normal and 
matched experimental data of lung adenocarcinoma, and all cancer cites 
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respectively. Differential expression results generated up- and downregulated 
genes with log 2 FC values (FC > 2). 
3.6. Results and Discussion 
3.6.1. Data Collection from TCGA 
The primary goal of gene expression profiling is to identify DEG. TCGA 
collected 497 clinical specimens from lung adenocarcinoma biopsies and 
expression data of 58 healthy lung specimens. TNM staging allowed tumour 
samples to be classified as either early stage or late stage lung adenocarcinoma, 
with stage I and II representing early stage, and III and IV late stage tumour, 
respectively (Detterbeck 2009). Categorizing specimens resulted in 394 early 
stage and 103 late stage specimens.  
Level 3 RNA RNAseq V2 data generated 20 531 genes expressed in healthy lung 
tissue, 5371 in early stage carcinogenesis and 20 351 in late stage LUAD, 
respectively (Figure 3.4). Comparison of expressed data showed that 15 160 of the 
genes are common to both normal lung tissue and late stage tumour, while 5371 
genes were found in all stages of disease and healthy samples. 
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Figure 3.4: Gene expression data of LUAD between classes (N, E and L) 
generated from TCGA Level 3 RNAseq V2 data depicted using Venny 2.0.2 - 
Computational Genomics Service (bioinfogp.cnb.csic.es/tools/venny). 
 
 
3.6.2. Statistical Analysis using MultiExperiment Viewer 
DEG of paired LUAD RNAseq V2 Level 3 data from TCGA were identified 
using MeV and normalized using RPKM. Parametric, unpaired t-Tests with 
multiple FDC were used to evaluate statistical significance between samples. The 
null hypothesis of this analysis was that there was no difference between the 
means of the two groups, and was rejected at p-values selected for each test 
performed (Table 3.1). 
Statistical significance of the DEG was evaluated by p-values generated for each 
sample (Subramanian et al. 2005). Hypothesis testing techniques such as t-Tests 
use information about the experimental design to identify a subset of genes that 
show statistical differences in patterns of expression across groups of samples 
(Saeed et al. 2006). Unpaired t-Tests compare the means of 2 independent 
samples. The null hypothesis, (presumed to be true), is that the 2 groups have the 
same average value with p-values indicating the accuracy of the null hypothesis 
(Cui et al. 2005). Small p-values denote a high probability of true difference in 
expression and a low probability that the observed difference occurred by chance 
(Morozova et al. 2008).  
Multiple hypothesis testing, such as GSEA analyses large lists of DEG and may 
result in an increased false discovery rate (FDR) since multiple annotations are 
tested (Draghici et al. 2007). FDR is a multiple testing error, controlled using 
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multiple FDCs, which is an important step in the analysis of RNAseq data (Kvam 
et al. 2012). Corrections such as Bonferroni, adjust p-values derived from multiple 
statistical tests to correct for false positives (Li et al. 2010). Permutation tests re-
samples n times the total number of observations, in a population sample, to build 
an estimate of the null distribution from which the test statistic has been drawn 
(Ge et al. 2003; Camargo et al. 2008). Fold change (FC) is a valuable complement 
to p-values and provides a way to assess differences between groups where p-
values may be significant due to large sample numbers and low sample variability 
within groups, but the actual difference in the magnitude, or FC, between groups 
is low (Dudoit et al. 2002; Morozova et al. 2008).  
The incorporation of multiple FDC and FC, into this study aimed to increase the 
statistical relevance of output data generated. For a gene to be significantly 
differentially expressed between the tumor and normal samples, it has to satisfy 
two conditions: FDR adjusted p-value and FC > 2 (Fonseca et al. 2014). The 
criterions were implemented in this study, to aid in identifying DEG with 
statistical relevance.  
Analysis of samples E vs. N identified both common and unique DEG for all 
parametric tests performed (Figure 3.5). From this output, 171 genes were 
statistically significant to this study, as they were enriched for all FDC parameters 
implemented. Genes found to be unique to a single test, or only commonly 
expressed in two were excluded from further analysis. Evaluation of statistical 
analysis performed on samples E vs. L identified only one significant output, 
 
 
 
 
 
 
` 98 
which was generated using a FDC of only α, no corrections and a p-value 
threshold of 0.01 (Figure 3.6).  
Analysis of N vs. L samples generated many outputs of interest, which may be 
pertinent to many biological systems (Figure 3.7). They were, however excluded 
from further investigation in this study, as a primary aim of this research was to 
identify DEG for the diagnosis of early stage LUAD. Statistically relevant genes 
from the tests of classes E vs. N and E vs. L were evaluated and compared to 
identify any overlap in data (Figure 3.8). No common genes were found between 
samples and therefore zero eliminated, resulting in a final DEG list of 171 
candidates identified from the group E vs. N. 
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Figure 3.5: DEG identified in classes E vs. N using MeV parametric t-Tests and 
multiple FDC (t-Test 1: p ≤ 0.01, no correction, t-Test 2: p ≤ 0.05 and Bonferroni, 
t-Test 3: p ≤ 0.05 and maxT) depicted using Venny 2.0.2 – Computational 
Genomics Service (bioinfogp.cnb.csic.es/tools/venny). 
Figure 3.6: Unique DEG between classes E vs. L identified using MeV parametric 
t-Test 1, p ≤ 0.01, depicted using Venny 2.0.2 – Computational Genomics Service 
(bioinfogp.cnb.csic.es/tools/venny). 
 
 
 
 
 
 
 
` 100 
Figure 3.7: DEG identified between classes N vs. L using parametric t-Tests and 
multiple FDC (t-Test 1: p ≤ 0.01, no correction, t-Test 2: p ≤ 0.05 and Bonferroni, 
t-Test 3: p ≤ 0.05 and maxT) in MeV, depicted using Venny 2.0.2 Computational 
Genomics Service (bioinfogp.cnb.csic.es/tools/venny). 
 
 
 
 
 
Figure 3.8: Unique DEG in classes E vs. N and E vs. L determined to be 
statistically significant following statistical analysis using MeV. Depicted using 
Venny 2.0.2 – Computational Genomics Service 
(bioinfogp.cnb.csic.es/tools/venny). 
3.6.3. Enrichment Analysis using Enrichr Feature and Annotation Tool 
The final candidate list of 171 DEG was uploaded to Enrichr for feature and 
annotation analysis. This tool computed enrichment for the input list against its 
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myriad of gene-set libraries (Huang et al. 2009). Comparison of enrichment 
signature patterns, between LUAD and its matched normal tissue counterpart, 
may aid in the identification of changes in critical biological regulatory 
mechanisms (Alexa et al. 2006). This knowledge may allow for the elucidation of 
disease specific genes involved in the process of carcinogenesis to be identified, 
enabling more accurate diagnosis (Huang et al. 2011). Enrichment scores were 
computed using three tests to rank relevance of queried genes against the gene set 
libraries. (1) The Fisher exact test, generated p-values, (2) a z-score test statistic, 
of the deviation from the expected rank of the Fisher exact test, and (3) a 
combined score, which multiplied the log of the given p-value by the computed z-
score (Chen et al. 2013). The Fisher exact test, commonly used in GSEA, makes 
no assumption about sample size. This assumption may affect the ranking of 
terms, based only on the length of the gene set, the z-score statistic is computed as 
a correction for this possible bias (Bullard et al. 2010). The incorporation of these 
scores as well as the computation of a combined test statistic into each category, 
provided increased statistical power (Azuaje 2014). To determine relevance of 
enriched results for the purpose of this analysis, p < 0.01, and combined scores 
(CS) > 2 were denoted as significant, and gene sets, incorporating less than 5 
overlaps were excluded. Characterisation of genetic expression patterns using 
ontologies, remains the most commonly used resource in uncovering molecular 
mechanisms associated with tumour initiation and progression (Young et al. 2010). 
Gene annotation provides a platform to facilitate the interpretation of gene 
signatures, in relation to its role in phenotypic diseases (Rhodes et al. 2007).  
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The Enrichr ontology annotation tool incorporates six gene-set libraries; GO 
Biological Process, GO Cellular Component, GO Molecular Function, MGI 
Mammalian Phenotype Level 3, MGI Mammalian Phenotype Level 4 and Human 
Phenotype Ontology. Querying of data against these libraries generated enriched 
terms from all but the latter (Table3.2).  
In the GO category of BP, terms of regulation of system process, secretion by cell, 
regulation of blood circulation and negative regulation of developmental growth 
were identified as enriched (Figure 3.9) (Table 3.2). Regulation and secretion are 
crucial to the cell-cycle, abnormal expression of factors involved in either of these 
processes have been identified in tumour formation (Lægreid et al. 2003).  
 
 
 
 
Figure 3.9: Histogram of enriched GO terms of BP generated from annotation 
analysis in Enrichr 
 
Investigation of CC terms identified this category to be most highly expressed of 
all queried gene set ontologies (Figure 3.10) (Table 3.2). Terms, extracellular 
region and extracellular space were identified as the most highly ranked and 
statistically significant in terms of p-values and CS. Cell surface and extracellular 
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annotations, presented as terms of interest in this study, as serum proteins are 
excreted extracellularly (Lai et al. 2009). These terms allowed for correlation of 
gene expression patterns, according to mechanisms which facilitated entry into 
circulation (Huang et al. 2007). Elucidation of genes signatures relating to these 
sub-categories would facilitate the identification of potential circulatory LUAD 
markers (Nogales-Cadenas et al. 2009). Molecular Function described the tasks 
performed by individual genes (Sherman et al. 2007). Evaluation of the data 
identified receptor activator activity and receptor regulator activity to be highly 
enriched (Figure 3.11) (Table 3.2). Exopeptidase activity, was also identified in 
MF terms, and is known to increase as a tumour transforms and proliferates 
(Villanueva et al. 2006).  
 
 
Figure 3.10: Histogram of enriched GO terms of CC generated from annotation 
analysis in Enrichr 
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Figure 3.11: Histogram of enriched GO terms of MF generated from annotation 
analysis in Enrichr 
 
Querying of the Midrand Graduate Institute (MGI) Mammalian Phenotype (MP) 
data enabled mammalian phenotypes to be annotated in the context of mutations 
and abnormal traits, used to model human disease biology. Different levels of 
phenotypic knowledge is supported and expressed, according to gene annotations 
(Smith et al. 2005). Investigation of Level 3 and 4 MP data revealed a trend in 
enriched abnormal neuronal terms (Table 3.2). Abnormal synaptic activity and 
abnormal neuron morphology was enriched in Level 4, while abnormal nervous 
system, presented with multiple terms in both levels. A pattern of abnormalities 
relating to the nervous system was seen in all output lists, and provided the 
analysis with an interesting theme (Table 3.2). 
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Table 3.2: Ontology enrichment terms extracted from Enrichr (p < 0.01, (CS) > 2) 
Term P-value 
Combine
d Score 
(CS) 
Source 
Regulation of system process  
(GO:0044057) 
0.000066301456224 8.43 
GO  
Biological 
Process 
(BP) 
Secretion by cell (GO:0032940) 0.000184527278327 8.15 
Regulation of blood circulation 
(GO:1903522) 
0.000336913928736 7.81 
Negative regulation of developmental 
growth (GO:0048640) 
0.000056995289897 7.77 
Extracellular region (GO:0005576) 0.000003314146713 21.77 
GO  
Cellular 
Component 
(CC) 
Extracellular space (GO:0005615) 0.000001231578227 18.93 
Synapse part (GO:0044456) 0.000027485228831 15.48 
Postsynaptic membrane (GO:0045211) 0.000043541600901 14.39 
Ion channel complex (GO:0034702) 0.000067021933900 13.68 
Synaptic membrane (GO:0097060) 0.000137750591689 12.74 
Transporter complex (GO:1990351) 0.000174426121335 12.58 
Transmembrane transporter complex 
(GO:1902495) 
0.000152213467642 12.53 
Cell surface (GO:0009986) 0.000296352725425 11.68 
Anchored component of membrane 
(GO:0031225) 
0.000298003137136 10.71 
Receptor activator activity 
(GO:0030546) 
0.000006295227776 17.80 
GO 
Molecular 
Function 
(MF) 
Receptor regulator activity 
(GO:0030545) 
0.000001903659722 17.10 
Ion channel activity (GO:0005216) 0.001313360572904 6.72 
Substrate-specific channel activity 
(GO:0022838) 
0.0015744937461720
44 
6.69 
Passive transmembrane transporter 
activity (GO:0022803) 
0.0022611910169902
31 
6.60 
Channel activity (GO:0015267) 
0.0022611910169902
31 
6.57 
Exopeptidase activity (GO:0008238) 
0.0021839180742638
35 
6.38 
Abnormal nervous system 
(MP0003633) 
0.0000060205033660
89 
10.37 
MGI 
Mammalia
n 
Phenotype 
Level 3 
Abnormal behavior (MP0004924) 
0.0000913945020256
39 
10.09 
Abnormal touch/nociception 
(MP0001968) 
0.0004225451865451
43 
9.33 
Abnormal muscle physiology 
(MP0002106) 
0.0010173792913535
20 
6.33 
Abnormal physiological response 
(MP0008872) 
0.0027168822393273
37 
5.57 
Abnormal nervous system 
(MP0003632) 
0.0003129401847408
73 
5.45 
Abnormal induced morbidity 
(MP0001657) 
0.0032315403923019
20 
5.07 
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Abnormal synaptic transmission 
(MP0003635) 
0.0000048882978824
83 
10.40 
MGI 
Mammalia
n 
Phenotype 
Level 4 
Abnormal nervous system 
(MP0002272) 
0.0006146689696155
86 
5.78 
Decreased physiological sensing 
(MP0008874) 
0.0017821265753240
83 
4.72 
Abnormal muscle fiber (MP0004087) 
0.0015456066378186
70 
4.44 
Abnormal neuron morphology 
(MP0002882) 
0.0004290949439187
47 
4.17 
Abnormal muscle contractility 
(MP0005620) 
0.0031912080243396
20 
3.69 
Abnormal pain threshold 
(MP0001970) 
0.0052571379470811
96 
3.49 
 
Carcinogenesis is a multifaceted phenomenon, involving changes in a multitude 
of cellular signaling mechanisms and pathways (Segal et al. 2004). Computational 
interrogation of specific regulatory networks of tumour cells, have revealed 
cryptic master regulator proteins, whose loss or gain affect the initiation and/or 
progression of carcinogenesis.  
These proteins have proven to be powerful ‘integrators’ of various genetic and 
epigenetic alterations, which contribute to malignant phenotypes and therefore 
hold great promise in biomarker discovery (Schreiber et al. 2010). To date, a 
multitude of cancer pathways have been elucidated, and identified aberrations in 
regulation of key proliferation and survival pathways, common to all cancers 
(Segal et al. 2004; Subramanian et al. 2005).  
Pathway analysis in Enrichr cross-referenced the candidate gene list against its 15 
incorporated libraries. KEGG pathways, presented neuroactive ligand receptor 
interaction, as the only term, which met the set parameters of this section of 
analysis, while a multitude of terms, were generated from WikiPathways and 
Reactome (Table 3.3). These terms included amongst others, neurotransmitter 
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receptor binding, GPCRs (G-protein coupled receptors), calcium regulation in the 
cardiac cell and transmission across chemical synapses.  
Lung cancers have been described to possess several neuropeptide receptors, as 
well as being able to synthesize and secrete various of these neuropeptides, 
thereby establishing autocrine-stimulated growth (Beekman et al. 1998). These 
peptides are part of a membrane receptor family, which initiates a cascade of 
intracellular signal transduction by interacting with G proteins and activating 
several kinase pathways and the mobilization of intracellular calcium (Ca
2+
), 
ultimately resulting in cell proliferation (Prassas et al. 2012). Kinase perturbations 
from Gene Expression Omnibus (GEO) identified BRD4 and AKT1 as proteins 
relevant to the gene set of interest (Table 3.3).  
Several hub protein-protein interactions (hub PPI) were expressed in this pathway 
analysis (Table 3.3). PPI hub, a small number of highly connected protein nodes, 
attempt to infer function to networks (Beekman et al. 1998). Gene encoded 
proteins can be expressed in increased quantities as a result of gene amplification, 
or through increased transcriptional activity, resulting in imbalances between gene 
repressors and gene activators (Kulasingam & Diamandis 2008). 
Although identification of these regulatory proteins revealed relationships to 
cancer pathways, their identification alone lacks specificity to disease diagnosis 
(Wing et al. 2011). Alterations in the modulators of signaling networks, specific 
to lung adenocarcinoma may facilitate the identification of diagnostic markers 
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(Makridakis & Vlahou 2010). 
Evaluation of disease/drugs libraries provided no meaningful data. While 
platforms of OMIM and Achilles, aimed at identifying and cataloging genetic 
vulnerabilities across diseases, generated several outputs, results were found to 
incorporate gene lists below the set threshold and/ or a significantly low CS < 2.  
Table 3.3: Pathway enrichment terms extracted from Enrichr (p < 0.01, (CS) > 2) 
Term P-value 
Combine
d Score 
Source 
Neuroactive ligand 
receptor interaction 
0.00443048485907919
2 
3.06 KEGG 
Non-odorant GPCRs 
(Mus musculus) 
0.00075073319118259
64 
7.28 
WikiPathways 
Calcium regulation in 
the cardiac cell 
(Homo sapiens) 
0.00322462435875148
1 
5.16 
Calcium regulation in 
the cardiac cell 
(Mus musculus) 
0.00264699333251841
7 
5.13 
GPCRs, other 
(Homo sapiens) 
0.00230020299762629
7 
4.99 
Adipogenesis genes 
(Mus musculus) 
0.00836209088503532
2 
3.89 
Neuronal system 
0.00075010074740886
4 
4.53 
Reactome 
Transmission across 
chemical synapses 
0.00195791471706012
7 
4.25 
Class A/1 
(Rhodopsin-like 
receptors) 
0.00597171128439237
8 
2.89 
Neurotransmitter 
receptor binding & 
downstream 
transmission - 
postsynaptic cell 
0.00804394544789450
3 
2.60 
NGF signaling via 
TRKA from the 
plasma membrane 
0.03492034654718689 2.10 
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DLG4 
0.00000028478289991
5 
14.61 
PPI Hub Protein 
CAMK2A 
0.00011556154483942
18 
10.14 
YWHAB 
0.00001897636077605
2 
7.84 
PRKACA 
0.00179856717598491
6 
6.39 
CALM1 
0.00405231320914435
9 
4.05 
FYN 
0.00874983512168222
8 
3.38 
BRD4 
0.00000000050167503
26 
26.32 Kinase 
Pertubations from 
GEO AKT1 
0.00475176034717670
4 
5.35 
 
In order to facilitate the discovery of potential circulatory biomarkers, candidate 
genes, most likely to be found in the extracellular exome were investigated using 
ontology annotation sources (as described in 3.5.2.2.1). Of the 171 DEG, 57 were 
identified as most likely to be secreted into circulation (Table 3.4). Of these genes, 
a large number were identified as cytokines and growth factors, including, 
ANGPTL7 (angiopoietin-like 7), EDN3 (endothelin 3), RETN (resistin), NRG3 
(neuregulin 3), CMTM2 (CKLF-like MARVEL transmembrane domain 
containing 2), CAMP (cathelicidin antimicrobial peptide), FGF10 (fibroblast 
growth factor 10), AGRP (agouti related neuropeptide), ANGPTL5 (angiopoietin-
like 5) and CMTM5 (CKLF-like MARVEL transmembrane domain containing 5). 
Cytokines and growth factors are signaling molecules, which regulate an array of 
biological processes such as cell proliferation, activation and differentiation by 
binding to specific receptors on the surface of their target cells and inducing 
intracellular signaling pathways (Welsh et al. 2003). The fibroblast growth factor 
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(FGF) family has been implicated in several disorders of bone growth, as well as 
in tumor formation and progression FGF10, a member of this family, has been 
proposed to play unique roles in the brain, in lung development, and wound 
healing (Beer et al. 2005).  
Table 3.4: Candidate genes identified as located in the extracellular cellular 
component using GO annotations and having the potential to be serum markers 
Potential Candidate Serum Markers 
ACR ACTN2 AGTR2 AGRP 
ANGPT
4 
ANGPT
L5 
ANGPT
L7 
ASPA C2orf40 C8B CA4 CAMP 
CD300L
G 
CD5L 
CMTM2 CMTM5 
CNKSR
2 
CPB2 CST5 CRHBP DPP6 
EDN3 ENPP6 FABP4 F11 
FAM150
B 
FGF10 FGFBP2 
FIGF GKN2 GPA33 GPC5 GPM6A ITLN2 KRT27 
LIN7A NRG3 ODAM OVCH1 OVCH2 PCDH15 
PLA2G1
B 
RS1 RSPO1 RSPO2 RETN SCUBE1 SFRP5 SH3GL2 
SIRPD 
SLC6A1
3 
TNR TRHDE UPK3B VWC2 WNT3A 
WNT7A 
      
 
Investigation of statistical, enrichment and annotation data identified 15 genes of 
interest (Table 3.5). Candidates displaying the largest FC and determined to be the 
most highly differentially expressed were selected from MeV based analysis. 
Enrichr results were curated based on the number of times genes were found 
expressed in terms of ontologies and/or pathways. The incorporation of enhanced 
annotation, together with the most highly ranked statistical and enrichment 
findings, assisted to more accurately identify outputs of interest. Of these genes of 
interest, IRX1 (iroquois homeobox 1), a homeodomain transcription factor known 
to play a critical role in cellular processes, presented as the most significantly 
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differentially expressed (Guo et al. 2010). ITLN2 (intelectin 2) and was also 
identified as expressed in several instances using enrichment analysis. DEG 
identified as having the potential to enter circulation, such as FGF10 and CD5L 
(CD5 molecule-like) were also expressed in several categories. FIGF (c-fos 
induced growth factor (vascular endothelial growth factor D)), also identified as 
VEGFD is a growth factor actively involved in the P13K-akt pathway, known to 
be mutated in tumours (Ding et al. 2008). 
Wingless type proteins (WNT) have a firmly established role in carcinogenesis. 
WNT7A, identified as a gene of interest, is a member of this family, identified as 
overexpressed in NSLC (Table3.4) (Kirikoshi & Katoh 2002). WNT signaling 
involves several other pathways including, Ca
2+ 
flux, protein kinase A, cJun N-
terminal kinase (JNK), and G protein, which have all been implicated in cancer 
(Brodie & Blumberg 2003; Stewart 2014). In normal tissue, WNT7A is associated 
with neuronal differentiation but has been identified as downregulated in almost 
all lung cancer types (Stewart 2014). 
The identification of, neuron signaling, receptor and membrane terms were 
frequently identified in this analysis. GRIA1 (glutamate receptor, ionotropic, 
AMPA 1) is often involved in synaptic transmission, Ca
2+ 
and kinase activity 
(Lisman et al. 2012). While cholinergic receptors CHRM1 (cholinergic receptor, 
muscarinic 1) and CHRM2 are known to be involved in G protein receptor 
activity and neurodegenerative disorders (Lai et al. 2001).  
 
 
 
 
 
 
` 112 
Table 3.5: Genes of interest identified using annotation, statistical analysis and 
enrichment analysis 
 
* DEG representing largest FC > 2 
** DEG expressed most often in terms of ontologies and/or pathways 
*** DEG identified as having the potential to be secreted into the extracellular exosome as well as 
presenting with multiple expressions in terms of ontologies and/or pathways  
Correlation of the candidate genes to lung cancer could possibly be identified 
following further investigation into their functioning and networks involvement 
(Ooi et al. 2009).  
3.6.4. Expression Analysis  
Enrichment analysis allowed for the identification of DEG, signifying statistically 
relevant biological differences between two test samples (Subramanian et al. 
2007). While DEG indicated changes in comparative expression levels, it was 
necessary to determine whether genes were up- or downregulated, to better 
evaluate biological mechanisms and functions (Nam & Kim 2008). Regulation of 
gene expression was evaluated, between matched samples in groups, normal and 
early LUAD, by comparison of their respective means. All of the 171 genes 
identified as differentially expressed were found to be downregulated in the 
MeV 
(Statistical Analysis)* 
Enrichr 
(Enrichment Analysis)** 
GO CC 
Extracellular Exosome*** 
IRX1 GRIA1 FGF10 
SLC6A CHRM2 WNT3A 
C13orf36 GRIK4 WNT7A 
ITLN2 AGTR2 FIGF 
CD300LG CHRM1 CD5L 
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cancer tissue (FC > 2) (Appendix A). To further assess these findings, genes were 
queried using GEA and MSigDB platforms. 
GEA differential expression data for LUAD provided validation to the 
observations of downregulation, of genes of interest (Table 3.5), SCL6A4, 
C13orf36, CD300LG, GRIA1, GRIK4, AGTR2, FGF10, FIGF, CD5L, WNT3A 
and WNT7A. No experimental data was available in GEA for remaining input 
genes of interest in relation to LUAD. 
Querying of the candidate genes (Table 3.5) against NCI-60 cell lines (National 
Cancer Institute) oncogenic signatures in MSigDB generated expression profiles 
showing both up and downregulation of genes (Appendix B). Of the eight lung 
cancer profiles available, five were identified as LUAD, namely, HOP92, HOP62, 
A549, NCI H23 and EKVX. Comparison of expression signatures yielded 
conflicting results. GRIA1 was seen to be downregulated in all LUAD except NCI 
H23, while FIFG presented with down regulation in LUAD and over expression 
in large cell lung cancer, NCI 460, and unspecified lung tumour cell line NCI 
H322. GRIK4 was identified as upregulated most lung cancers, showing a 
particularly high expression profile for squamous cell lung cancer line, NCI H226. 
CD5L was also seen to present with moderate upregulation in most lung cancers 
except EKVX. Analysis of these profiles yielded no definitive upregulation of any 
of the genes of interest queried. Variability across studies could arise due to 
biological differences amongst samples and populations or technological 
differences between the platforms. Gene expression profiling patterns could 
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facilitate in distinguishing the major morphological classes of lung tumours as 
well as enable subgroups of adenocarcinomas to be defined (Parmigiani et al. 
2004). 
Evaluation of the 57 potential serum markers, identified as downregulated, using 
MsigDB NCI-60 ocogenic signatures lead to no conclusive upregulation of 
candidate genes (Appendix C). Confirmation of these findings would need to be 
assessed using wet lab techniques such as RT PCR. 
 
 
3.7. Discussion and Conclusion 
The identification of candidate serum markers and genes of interest (Table 3.4) 
(Table 3.5) may hold relevant implications into understanding mechanisms 
involved in lung adenocarcinoma initiation and progression. However, they did 
not meet the criteria in order to facilitate identifying early stage circulatory 
markers, specific to the disease phenotype.  
Genetic alterations in tumour tissue often involves growth-stimulatory autocrine 
and paracrine signaling (Hanahan & Weinberg 2011). Two distinct genetic 
alterations are involved in tumour development, the activation of oncogenes and 
the inactivation of tumor suppressor genes. While oncogenes drive abnormal cell 
proliferation as a consequence of genetic alterations that increase gene expression, 
tumor suppressor genes act to inhibit cell proliferation and tumor development. In 
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many tumors, these genes are lost or downregulated, removing negative regulators 
of cell proliferation and contributing to the abnormal proliferation of tumor cells 
(Cooper & Sunderland 2000). 
Despite, several of the identified candidate markers offering links to these 
networks, for a protein to be useful in diagnosis it is necessary that it be highly 
expressed in comparison to its normal counterpart (Welsh et al. 2003). The 
principle behind the discovery of serum biomarkers require that the tumour 
secrete these product at an elevated level into bodily fluids (Diamandis 2004). As 
a tumour develops, proteins required for growth and metastasis are secreted and 
sheds cells into the circulation (Patz et al. 2007). The upregulation of DEG, is 
therefore of critical importance in the identification of tissue specific circulatory 
markers (Hassanein et al. 2012). 
Lung cancer is currently classified according to morphologically as squamous cell 
carcinoma, adenocarcinoma, small cell carcinoma, and large cell carcinoma. This 
classification, however is often ineffective in predicting the biological behavior of 
these cancers. Gene expression profiles report distinct molecular profiles which 
has lead to refinement of classification (Parmigiani et al. 2004). Global gene 
expression profiling has routinely been used to uncover the underlying differences 
between normal and cancer cells, and these signatures are commonly used in 
facilitating diagnosis and prognosis of lung cancer (Ben-hamo et al. 2013). 
However to a large extent, expression profiling has failed to uncover genes that 
are upregulated and involved in cancer initiation, as the overlap at the gene level 
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between profiles is often poor, resulting in questioning of their robustness (Rapin 
et al. 2014). As most studies compare cancer with cancer, many of the detected 
transcriptional changes between different cancer samples may be attributed to 
differences in cell type and developmental stage and, consequently, will not 
identify gene expression signatures that underlie the malignant phenotype of 
interest (Rapin et al. 2014). 
Overexpressed genes provide relevance not only for diagnosis, but because they 
constitute potential targets for therapeutic intervention. Expressed genes are a 
major determinant of cellular phenotype and function and are also responsible for 
variation of cellular responses to environmental stimuli (Chengalvala et al. 2007). 
Gene expression offers assistance to guide drug discovery by illustrating 
involvement of the desired cellular pathways, as well as avoidance of acting on 
the toxicological pathways (Bai et al. 2013).  
Investigation of DEG aimed to identify candidates, which were seen to be 
overexpressed in LUAD in order to facilitate biomarker discovery. However, all 
genes presented as being downregulated, resulting in no classic biomarker being 
identified in this analysis.  
Studies by Danielsson and colleagues (2013) identified the majority of genes 
involved in malignant transformation to be downregulated, with only 20 % of 
genes evaluated being over expressed. While upregulated genes were seen as 
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being involved in cellular proliferation control, downregulated genes consisted of 
proteins exposed or secreted from the cell surface (Danielsson et al. 2013). 
Altogether, the RNAseq data showed that in early stage LUAD, the enriched 
group of 171 genes presented as downregulated and related to a diverse set of 
functions, such as receptor binding and signaling, as well as consisting of a large 
proportion of cytokines and growth factors. To fully understand lung cancer 
dysregulation, as well as the potential of these genes being tumour suppressors, 
further evaluation of protein expression pattern and function of the proteins in 
vitro and in vivo is needed (Volinia et al. 2006). 
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Chapter 4 
Future Perspectives 
Diagnostic biomarker development is based on the biological properties of cancer as 
a systemic disease, and entails the search for plasma proteins identified as over 
expressed by the tumour tissue when compared to its normal counterpart (Hanash et 
al. 2008). Classification of lung cancer has traditionally been based on tumour 
morphology. However, tumours identified as histologically similar can exhibit 
different responses to therapy, denoting variations at the molecular level (Cuperlovic-
Culf et al. 2005). 
Therefore, identification of circulatory tumour specific markers, could provide an 
early, rapid and non-invasive diagnostic technique which would most certainly 
improve the prognosis of patients with lung carcinomas (Altintas & Tothill 2013). 
Gene expression data, obtained using high throughput (HT) technologies offers an 
ideal platform to facilitate biomarker discovery (Prassas et al. 2012).  
RNAseq allows for whole transcriptome profiling using deep sequencing. This 
technique compares favorably to previously used methods for gene expression 
measurement, such as DNA microarrays. This is due to be its higher sensitivity, lower 
background and ability to detect previously unknown transcripts (Howe et al. 2011).  
Microarray analysis has become a widely used tool in the interrogation of gene 
expression data in many biological settings. The ability of these arrays to 
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simultaneously interrogate thousands of transcripts, has led to several insights into 
developmental processes and differences in gene expression between samples (Choi 
et al. 2014). Microarray data, however, presents with several limitations, which have 
hindered the development and acceptance of markers based on their profiling. These 
include the use of multiple platforms and protocols in determining differential 
expression profiles as well as the lack of assay reproducibility on multiple samples of 
the same tissue specimen (Simon 2003). Classes used in comparison of expression 
profiling may represent different tumour types and therefore not yield tissue specific 
gene expression (Szczurek et al. 2010). Accurate identification of DEG, requires 
high-quality specimens with well-matched controls, and an efficient process to 
confirm discoveries through independent validation studies (Hanash et al. 2008). 
RNAseq technologies, unlike array sequencing, allow for the mapping of previously 
unknown organisms and do not require the use of probes (Oshlack et al. 2010). While 
cross-hybridization of microarray probes affect expression measures non-uniformly 
(Petryszak et al. 2014).  
RNAseq also presents with the advantage of analyzing expression at exon levels, and 
provides detail about transcriptional features that arrays are not able to. Novel 
transcribed regions, splicing variants and allele-specific expression can be identified 
using this technology, reflecting the high overall sensitivity of RNAseq compared 
with other whole-transcriptome expression quantification platforms (Huang et al. 
2011; Trapnell et al. 2012). 
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The overall advantages provided by RNAseq, allow for the more accurate assessment 
of DEG. Genes identified as potential candidate markers (Chapter 2), COPZ1, 
SEC23B, SEC24A and SEC24D, did not present as differentially expressed using this 
NGS platform, and were also found to be located in GO cellular components, which 
would not facilitate secretion into the extracellular exosome. In addition, none of the 
4 above mentioned potential candidate genes were identified using RNAseq (Chapter 
3). This in Combination with their intracellular predisposition eliminated them as 
potential circulatory markers for early lung cancer diagnosis. 
The 57 potential serum markers and 10 genes of interest identified as downregulated 
(Chapter 3) would require validation at a molecular level. Quantitative real-time PCR, 
(RT PCR) is a tool commonly used when validating HT gene expression results 
(Morey et al. 2006). Changes in gene expression at the RNA level would then need to 
be evaluated at the protein level, with several techniques such as, 
immunofluorescence (IM) microscopy, two- dimensional polyacrylamide gel 
electrophoresis (2D-PAGE), surface enhanced laser desorption/ionisation time of 
flight (SELDI-ToF), protein arrays, isotope coded affinity tags (ICAT), and 
multidimensional protein identification technology (MudPIT) currently used (Berriz 
et al. 2009; Danielsson et al. 2013). 
Genes identified as downregulated in cancer may reveal themselves to be tumour 
suppressor genes, which encode proteins that normally inhibit the formation of 
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tumours (Kumar et al. 2005). Inactivation of both copies of a tumor suppressor gene 
is required before their function can be eliminated, and thus further investigation of 
these genes is necessary to accurately assess their roles in tumourigenesis. While the 
genes identified may not be targets as diagnostic tools for early stage lung cancer, 
they might however reveal novel pathways implicated in tumorigenesis (Westbrook 
et al. 2005). 
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Appendix A: Average sample means of groups early versus normal lung cancer 
used to identify genes as downregulated (FC > 2) 
GENE ID 
GroupA (normal) 
Mean Average 
GroupB (early)  
Mean Average 
FC 
ABCC13|150000 4,2816224 1,4065871 3,043979573 
ACADL|33 9,009417 4,443536 2,027533253 
ACR|49 2,6779847 1,0424821 2,568854372 
ADCY8|114 5,6271825 0,9243555 6,087682174 
ADCYAP1R1|117 1,7422048 0,4905618 3,551448156 
ADH1A|124 6,1923056 2,2539406 2,74732422 
ADRA1A|148 4,755768 0,9787929 4,858809254 
ADRA1D|146 5,065104 2,3533425 2,152302098 
AGBL1|123624 3,967218 0,9221507 4,302136299 
AGRP|181 5,0293627 1,5410669 3,263558967 
AGTR2|186 9,102922 4,2310033 2,151480714 
ANGPT4|51378 4,962274 1,6346674 3,035647496 
ANGPTL5|253935 3,3710234 0,8047033 4,189150709 
ANGPTL7|10218 4,5971813 0,8931059 5,147408947 
ANKRD1|27063 9,901326 4,0223947 2,461550081 
ANO2|57101 5,1373405 2,4721 2,07812811 
ART4|420 5,445078 2,58589 2,105688177 
ASPA|443 5,4383144 2,2289684 2,439834679 
BAI3|577 5,414573 2,5566201 2,117863737 
BET3L|100128327 1,3542717 0,29541817 4,58425323 
BTBD18|643376 1,1017184 0,41362333 2,663578962 
BTNL3|10917 2,1138666 0,8886269 2,378801047 
C10orf67|256815 6,4371624 1,3119464 4,906574232 
C13orf36|400120 8,287082 0,7133158 11,61769023 
C15orf51|196968 2,8569746 1,3251755 2,155921687 
C19orf69|10017076
5 
1,4497871 0,25641677 5,654026061 
C1orf150|148823 4,702532 2,337855 2,01147291 
C20orf202|400831 5,0562468 2,2932894 2,204801016 
C21orf71|282566 1,2679096 0,35393432 3,582330191 
C2orf40|84417 7,753121 3,732006 2,077467453 
C8B|732 7,6111403 2,8394043 2,680541232 
CA4|762 9,431905 3,4145806 2,762244066 
CAMP|820 5,6810355 1,7828605 3,186472245 
CASP12|120329 3,6950889 0,8951441 4,127926331 
CASP5|838 3,9735572 1,9769943 2,009898157 
CASQ2|845 6,5151634 3,0123134 2,162843813 
GENE ID GroupA (normal) GroupB (early)  FC 
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Mean Average Mean Average 
CCDC141|285025 7,720403 3,4250622 2,254091327 
CCDC54|84692 1,389033 0,1639819 8,470648285 
CD300LG|146894 9,059065 0,7597923 11,92308082 
CD5L|922 5,2576313 0,98691463 5,327341535 
CDH19|28513 4,6428785 1,3723037 3,383273324 
CHRM1|1128 6,2181664 1,3174869 4,71971782 
CHRNA2|1135 3,9502168 0,5350508 7,382881775 
CMTM2|146225 4,3510895 1,782931 2,440413847 
CMTM5|116173 2,6354039 0,41136432 6,406496071 
CNKSR2|22866 5,233461 2,3568158 2,220564288 
CNTFR|1271 5,1314034 1,6777856 3,058438098 
CNTN6|27255 8,261649 2,7290616 3,027285643 
CPB2|1361 9,513501 3,9313664 2,419896807 
CRHBP|1393 2,8420057 1,353906 2,099115965 
CST5|1473 4,5923557 1,912013 2,401843345 
CYP3A7|1551 4,765544 0,8792027 5,420301826 
DCC|1630 5,146027 1,9704973 2,611537199 
DPP6|1804 5,502035 1,8839203 2,920524292 
EDN3|1908 4,3012714 1,0384432 4,142038197 
ELMOD1|55531 3,9549534 1,6000018 2,471843094 
EMR3|84658 6,095803 2,4613633 2,476596202 
ENDOU|8909 3,0747228 0,92509377 3,323687717 
ENPP6|133121 4,228245 2,0811806 2,031656935 
ERVFRDE1|405754 4,5414157 1,5628172 2,905916124 
F11|2160 7,680035 2,7858522 2,756799158 
FABP4|2167 11,316286 5,073104 2,230643409 
FAM150B|285016 6,6600966 2,5018952 2,662020615 
FAM189A1|23359 6,1947474 2,9185467 2,122545238 
FGF10|2255 2,8450553 0,5674932 5,013373376 
FGFBP2|83888 6,5299954 2,6398761 2,473599197 
FIGF|2277 10,009997 4,9667354 2,015407747 
FLJ37543|285668 1,3223774 0,2869659 4,608134277 
G6PC2|57818 1,4373262 0,51902586 2,76927666 
GATA1|2623 3,1759634 1,0285112 3,087923009 
GBP7|388646 1,9383273 0,65805346 2,945546856 
GKN2|200504 9,943389 4,5074315 2,205998915 
GPA33|10223 8,136766 3,9195318 2,075953562 
GPC5|2262 6,043915 2,829931 2,135711083 
GPM6A|2823 10,239844 4,1057186 2,494044283 
GENE ID GroupA (normal) GroupB (early)  FC 
 
 
 
 
 
 
 137 
Mean Average Mean Average 
GPR182|11318 2,9909582 1,3553613 2,20676081 
GRIK4|2900 5,1211247 1,8573241 2,757259597 
GYPE|2996 6,508371 2,5807354 2,521905578 
HEMGN|55363 1,961249 0,49257186 3,981650515 
HSPB3|8988 4,002853 1,2937107 3,094086645 
IRX1|79192 6,8954196 0,208589 33,05744598 
ITLN2|142683 9,015552 0,7992436 11,28010534 
KCNA4|3739 5,6196437 1,1358455 4,947542337 
KCNIP1|30820 4,059912 1,5854095 2,560797069 
KLF17|128209 3,4848986 1,2275481 2,838910019 
KLHL33|123103 1,6128268 0,42417312 3,802284313 
KRT27|342574 3,3772027 1,0924238 3,091476678 
KRT4|3851 9,495609 4,7258854 2,009276188 
LGI3|203190 10,864179 4,12859 2,631450205 
LHFPL3|375612 6,105437 2,6559932 2,298739696 
LIN7A|8825 6,173955 2,86324 2,156282743 
LOC257358|257358 2,5526803 0,9995538 2,553819814 
LOC283392|283392 3,317297 0,8327328 3,983627161 
LOC400804|400804 1,6195064 0,31280133 5,177428114 
LOC572558|572558 1,7571205 0,5157032 3,407232106 
LOC723809|723809 7,9251947 3,939973 2,01148452 
LOC90586|90586 2,8907733 1,1384894 2,539130623 
LOXHD1|125336 4,5330167 1,8289431 2,478489735 
LRRTM4|80059 3,78329 1,3709701 2,759571489 
MAP3K15|389840 4,5975385 1,5455241 2,974743972 
MAPK4|5596 8,137145 4,012172 2,028114697 
MGC27382|149047 4,5428805 1,0652946 4,264435866 
MUSK|4593 3,5123036 1,0806131 3,250287823 
NKAPL|222698 4,4268036 2,151486 2,057556312 
NRG3|10718 4,8136506 1,4317902 3,361980407 
NTNG1|22854 7,0784 3,51211 2,015426624 
ODAM|54959 5,7103567 1,2218052 4,673704695 
ODF3L1|161753 5,379729 2,6711323 2,014025662 
OR2W3|343171 3,0378652 0,52102745 5,830528123 
OTC|5009 3,2612658 0,63570565 5,130150723 
OVCH1|341350 5,3197083 1,86584115 2,851104608 
OVCH2|341277 3,895136 1,7016311 2,289060185 
P2RX6|9127 4,0380263 1,8500171 2,182696744 
PAK7|57144 2,4745655 0,82410604 3,002727052 
GENE ID GroupA (normal) GroupB (early)  FC 
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Mean Average Mean Average 
PLA2G1B|5319 8,445295 4,0442 2,088248603 
PRKG2|5593 7,2551813 3,5093539 2,067383771 
PTCRA|171558 4,992306 2,3703027 2,106189222 
PTPRQ|374462 6,7849884 1,4416903 4,706273185 
PURG|29942 2,1752582 1,0161554 2,140674743 
RANBP3L|202151 5,180508 2,4948077 2,076515958 
RBP2|5948 5,118596 1,0438054 4,90378379 
RETN|56729 7,533858 3,046637 2,472843992 
RMST|196475 2,2621553 0,69590604 3,250661972 
RPH3A|22895 3,6431863 1,1569144 3,149054329 
RPL13AP17|399670 7,67246 2,390377 3,209728005 
RPL23AP32|56969 2,078843 0,48285732 4,305294574 
RSPO1|284654 6,767636 2,53213 2,672704798 
RSPO2|340419 7,202499 3,2611396 2,208583466 
RXFP1|59350 6,3622127 2,4175732 2,63165256 
RXRG|6258 6,8258986 2,735596 2,495214425 
SCUBE1|80274 8,760947 4,111886 2,130639565 
SFRP5|6425 6,79853 2,938662 2,313478039 
SGCG|6445 6,458385 1,7367709 3,718616543 
SH2D4B|387694 4,3255267 1,5447667 2,800116484 
SH3GL2|6456 5,9703283 1,7873415 3,340339997 
SH3GL3|6457 6,5783734 1,1899475 5,528288769 
SIRPD|128646 2,6429155 0,5804424 4,55327781 
SLC27A6|28965 5,0158305 1,2780949 3,924458583 
SLC5A4|6527 3,5556588 1,1802734 3,012572172 
SLC6A13|6540 4,638028 0,2026144 22,89091002 
SLC6A4|6532 10,887906 2,64655 4,113999736 
SLCO1A2|6579 7,279196 2,0216997 3,60053276 
SLITRK2|84631 5,016351 1,5283369 3,282228545 
SOSTDC1|25928 9,003033 3,5778239 2,516343244 
ST8SIA6|338596 5,702789 1,6818341 3,39081542 
SYN2|6854 5,596719 1,6770558 3,337228851 
SYNPO2L|79933 4,9549394 1,9781082 2,504887953 
TCEAL2|140597 6,9793286 3,1712759 2,200795144 
TMEM132C|92293 5,0876803 1,8587906 2,737091687 
TNR|7143 3,716323 0,63475776 5,854710622 
TRHDE|29953 6,973898 2,420352 2,881356927 
TRIM58|25893 6,4378753 2,6731522 2,40834596 
UNC45B|146862 4,3746734 1,6354035 2,674981067 
GENE ID GroupA (normal) GroupB (early)  FC 
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Mean Average Mean Average 
UPK3B|80761 11,248419 5,334326 2,108686083 
VWC2|375567 2,0223505 0,47118497 4,292052227 
WNT3A|89780 8,14199 2,8524773 2,854357509 
WNT7A|7476 7,4504957 3,3099694 2,250925854 
ZCCHC5|203430 1,6827285 0,58805156 2,861532244 
ZDHHC19|131540 3,0852334 0,8454799 3,649091362 
ZNF536|9745 2,849423 0,742615 3,837012449 
ZNF705A|440077 0,89204854 0,35725042 2,49698388 
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Appendix B: Heat map visulisation of oncogenic signatures of candidate genes of interest generated by the Molecular Signatures 
Database (MSigDB) NCI-60 cell line (National Cancer Institute) with red indicating upregulation and blue depicting 
downregulation (http://www.broadinstitute.org/msigdb). 
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Appendix C: Heat map visulisation of oncogenic signatures of candidate serum markers generated by the Molecular Signatures 
Database (MSigDB) NCI-60 cell line (National Cancer Institute) with red indicating upregulation and blue depicting 
downregulation (http://www.broadinstitute.org/msigd 
 
 
 
 
 
 
 
 
